Lyumjev Prescribing Information

Drug Detail:Lyumjev (Insulin lispro [ in-soo-lin-liss-pro ])

Drug Class: Insulin

Highlights of Prescribing Information

These highlights do not include all the information needed to use LYUMJEV safely and effectively. See full prescribing information for LYUMJEV.

LYUMJEV (insulin lispro-aabc) injection, for subcutaneous or intravenous use
Initial U.S. Approval: 2020

Recent Major Changes

Indications and Usage (1)

10/2022

Indications and Usage for Lyumjev

LYUMJEV® is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. (1)

Lyumjev Dosage and Administration

See Full Prescribing Information for important administration instructions. (2.1, 2.2)
Subcutaneous Injection (2.2):
- Administer LYUMJEV U-100 or U-200 at the start of a meal or within 20 minutes after starting a meal subcutaneously into the abdomen, upper arm, thigh, or buttocks.
- Rotate injection sites within the same region to reduce risk of lipodystrophy and localized cutaneous amyloidosis.
- Should generally be used in regimens with an intermediate or long-acting insulin.
Continuous subcutaneous infusion (Insulin Pump) (2.2):
- Refer to the insulin infusion pump user manual to see if LYUMJEV can be used. Use in accordance with the insulin pump instructions for use.
- Administer LYUMJEV U-100 by continuous subcutaneous infusion using an insulin pump in a region recommended in the instructions from the pump manufacturer. Rotate infusion sites within the same region to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.
- Do not administer LYUMJEV U-200 by continuous subcutaneous infusion.
Intravenous Infusion (2.2):
- Administer LYUMJEV U-100 intravenously only under medical supervision. DO NOT administer LYUMJEV U-200 by intravenous infusion.
- Dilute LYUMJEV U-100 to a concentration of 1 unit/mL.
Individualize and adjust the dosage of LYUMJEV based on the patient's metabolic needs, glucose monitoring results, and glycemic control goal. (2.3)
Dose adjustments may be needed when switching from another insulin, with changes in physical activity, changes in concomitant medications, changes in meal patterns (i.e., amount and type of food, timing of food intake), changes in renal or hepatic function, or during acute illness. (2.3)

Dosage Forms and Strengths

Injection: 100 units/mL (U-100) available as:

10 mL multiple-dose vial (3)
3 mL single-patient-use KwikPen® (3)
3 mL single-patient-use Junior KwikPen® (3)
3 mL single-patient-use Tempo Pen® (3)
3 mL single-patient-use cartridges (3)

Injection: 200 units/mL (U-200) available as:

3 mL single-patient-use KwikPen® (3)

Contraindications

During episodes of hypoglycemia. (4)
Hypersensitivity to insulin lispro-aabc or any of the excipients in LYUMJEV. (4)

Warnings and Precautions

Never share a LYUMJEV prefilled pen or cartridge between patients, even if the needle is changed. (5.1)
Hyperglycemia or hypoglycemia with changes in insulin regimen: Make changes to a patient's insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of glucose monitoring. (5.2)
Hypoglycemia: May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness. (5.3)
Hypoglycemia due to medication errors: Accidental mix-ups between insulin products can occur. Instruct patients to check insulin labels before injection. Do not transfer LYUMJEV U-200 from the LYUMJEV KwikPen to a syringe as overdosage and severe hypoglycemia can result. (5.4)
Hypokalemia: May be life-threatening. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated. (5.5)
Hypersensitivity reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue LYUMJEV, monitor, and treat if indicated. (5.6)
Fluid retention and heart failure with concomitant use of thiazolidinediones (TZDs): Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation of TZD if heart failure occurs. (5.7)
Hyperglycemia and ketoacidosis due to insulin pump device malfunction: Monitor glucose and administer LYUMJEV by subcutaneous injection if pump malfunction occurs. (5.8)

Adverse Reactions/Side Effects

Adverse reactions observed with LYUMJEV include hypoglycemia, injection/infusion site reactions, allergic reactions, rash, pruritus, lipodystrophy, and weight gain. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

Drugs that Increase Hypoglycemia Risk or Increase or Decrease Blood Glucose Lowering Effect: Adjustment of dosage may be needed; closely monitor blood glucose. (7)
Drugs that Blunt Hypoglycemia Signs and Symptoms (e.g., beta-blockers, clonidine, guanethidine, and reserpine): Increased frequency of glucose monitoring may be required. (7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 10/2022

Full Prescribing Information

1. Indications and Usage for Lyumjev

LYUMJEV® is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

2. Lyumjev Dosage and Administration

2.1 Important Administration Instructions

Always check insulin labels before administration [see Warnings and Precautions (5.4)].
Inspect LYUMJEV visually before use. It should appear clear and colorless. Do not use LYUMJEV if particulate matter and discoloration is seen.
Use LYUMJEV prefilled pens with caution in patients with visual impairment that may rely on audible clicks to dial their dose.
Do not perform dose conversion when using any LYUMJEV U-100 or U-200 prefilled pens. The dose window of LYUMJEV prefilled pens shows the number of units of LYUMJEV to be delivered and no conversion is needed.
Do not transfer LYUMJEV U-200 from the prefilled pen to a syringe for administration [see Warnings and Precautions (5.4)].
Do not mix LYUMJEV with any other insulin products.
Do not administer LYUMJEV U-200 using continuous subcutaneous infusion insulin pump.
Do not administer LYUMJEV U-200 intravenously.

2.2 Route of Administration Instructions

Subcutaneous Injection for LYUMJEV U-100 or U-200

Administer LYUMJEV at the start of a meal or within 20 minutes after starting a meal subcutaneously into the abdomen, upper arm, thigh, or buttocks.
Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Adverse Reactions (6.1, 6.2)].
LYUMJEV given by subcutaneous injection should generally be used in regimens with intermediate or long-acting insulin.
The LYUMJEV U-100 KwikPen, LYUMJEV U-100 Tempo Pen, and LYUMJEV U-200 KwikPen each dial in 1 unit increments and deliver a maximum dose of 60 units per injection.
The LYUMJEV U-100 Junior KwikPen dials in 0.5 unit increments and delivers a maximum dose of 30 units per injection.

Continuous Subcutaneous Insulin Infusion (Insulin Pump) for LYUMJEV U-100 Only

Do not administer LYUMJEV U-200 using an insulin pump.
Refer to the continuous subcutaneous insulin infusion pump user manual to see if LYUMJEV can be used with the insulin pump. Use LYUMJEV in accordance with the insulin pump system's instructions for use.
Administer LYUMJEV U-100 by continuous subcutaneous infusion in a region recommended in the instructions from the pump manufacturer. Rotate infusion sites within the same region to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not infuse into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)].
Train patients using continuous subcutaneous insulin infusion (CSII) therapy to administer insulin by injection and have alternate insulin therapy available in case of insulin pump failure [see Warnings and Precautions (5.8)].
Change LYUMJEV U-100 in the pump reservoir at least every 9 days or according to the pump user manual, whichever is shorter.
Change the infusion sets and the infusion set insertion site according to the manufacturer's user manual.
Do not dilute or mix LYUMJEV U-100 when administering by CSII.
Do not expose LYUMJEV in the pump reservoir to temperatures greater than 98.6°F (37°C).

Intravenous Administration for LYUMJEV U-100 Only

Do not administer LYUMJEV U-200 intravenously.
Administer LYUMJEV U-100 intravenously only under medical supervision with close monitoring of glucose and potassium levels to avoid hypoglycemia and hypokalemia [see Warnings and Precautions (5.3, 5.5)].
Dilute LYUMJEV U-100 to a concentration of 1 unit/mL using 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP infusion solutions. Dilutions to concentrations below 1 unit/mL are not recommended.
Diluted LYUMJEV may be stored for up to 4 days when refrigerated or up to 12 hours at room temperature [see HOW SUPPLIED/STORAGE AND HANDLING (16.2)].

2.3 General Dosage Instructions

Individualize and adjust the dosage of LYUMJEV based on the patient's metabolic needs, glucose monitoring results, and glycemic control goal.
If converting from another mealtime insulin to LYUMJEV, the change can be done on a unit-to-unit basis.
Dosage adjustments may be needed when switching from another insulin, with changes in physical activity, changes in concomitant medications, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness to minimize the risk of hypoglycemia or hyperglycemia [see Warnings and Precautions (5.2, 5.3), Drug Interactions (7) and Use in Specific Populations (8.6, 8.7)].
During changes to a patient's insulin regimen, increase the frequency of glucose monitoring [see Warnings and Precautions (5.2)].
Instruct patients who forget a mealtime dose to monitor their glucose level to decide if an insulin dose is needed, and to resume their usual dosing schedule at the next meal.

3. Dosage Forms and Strengths

Injection: 100 units/mL (U-100) clear and colorless solution available as:

10 mL multiple-dose vial
3 mL single-patient-use LYUMJEV KwikPen
3 mL single-patient-use LYUMJEV Junior KwikPen
3 mL single-patient-use LYUMJEV Tempo Pen
3 mL single-patient-use cartridges

Injection: 200 units/mL (U-200) clear and colorless solution available as:

3 mL single-patient-use LYUMJEV KwikPen

4. Contraindications

LYUMJEV is contraindicated:

during episodes of hypoglycemia.
in patients with hypersensitivity to insulin lispro-aabc or any of the excipients in LYUMJEV.

5. Warnings and Precautions

5.1 Never Share a LYUMJEV Prefilled Pen, Cartridge, or Syringe Between Patients

LYUMJEV prefilled pens or cartridges should never be shared between patients, even if the needle is changed. Patients using LYUMJEV vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen

Changes in an insulin regimen (e.g., insulin, insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia [see Warnings and Precautions (5.3)] or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia [see Adverse Reactions (6.1)].

Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

5.3 Hypoglycemia

Hypoglycemia is the most common adverse reaction associated with insulins, including LYUMJEV [see Adverse Reactions (6.1)]. Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). LYUMJEV, or any insulin, should not be used during episodes of hypoglycemia [see Contraindications (4)].

Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7)], or in patients who experience recurrent hypoglycemia.

Risk Factors for Hypoglycemia

The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulation. As with all insulins, the glucose lowering effect time course of LYUMJEV may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature [see Clinical Pharmacology (12.2)]. Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication [see Drug Interactions (7)]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.6, 8.7)].

Risk Mitigation Strategies for Hypoglycemia

Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of glucose monitoring is recommended.

5.4 Hypoglycemia Due to Medication Errors

Accidental mix-ups between insulin products have been reported. To avoid medication errors between LYUMJEV and other insulins, instruct patients to always check the insulin label before each injection.

Do not transfer LYUMJEV U-200 from the LYUMJEV KwikPen to a syringe. The markings on the insulin syringe will not measure the dose correctly and can result in overdosage and severe hypoglycemia [see Dosage and Administration (2.1) and Warnings and Precautions (5.3)].

5.5 Hypokalemia

All insulins, including LYUMJEV, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).

5.6 Hypersensitivity Reactions

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including LYUMJEV [see Adverse Reactions (6.1)]. If hypersensitivity reactions occur, discontinue LYUMJEV; treat per standard of care and monitor until symptoms and signs resolve. LYUMJEV is contraindicated in patients who have had hypersensitivity reactions to insulin lispro-aabc or any of its excipients [see Contraindications (4)].

5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-Gamma Agonists

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including LYUMJEV, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.

5.8 Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction

Pump or infusion set malfunctions can lead to a rapid onset of hyperglycemia and ketoacidosis. Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary. Interim therapy with subcutaneous injection of LYUMJEV may be required. Patients using continuous subcutaneous insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure [see Dosage and Administration (2.2), How Supplied/Storage and Handling (16.2), and Patient Counseling Information (17)].

6. Adverse Reactions/Side Effects

The following adverse reactions are also discussed elsewhere:

Hypoglycemia [see Warnings and Precautions (5.3)].
Hypoglycemia Due to Medication Errors [see Warnings and Precautions (5.4)]
Hypokalemia [see Warnings and Precautions (5.5)].
Hypersensitivity Reactions [see Warnings and Precautions (5.6)].

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates actually observed in clinical practice.

Adverse Reaction Database – Adult Patients with Type 1 and Type 2 Diabetes

The data in Table 1 reflect the exposure of 780 adult patients with type 1 diabetes to LYUMJEV with a mean exposure duration of 26 weeks [see Clinical Studies (14.2)]. The mean age was 44 years, the mean duration of diabetes was 19 years, 55% were male, 77% were White, 2% were Black or African American, and 9% were Hispanic. The mean BMI was 26.6 kg/m2 and the mean HbA1c at baseline was 7.3%.

The data in Table 2 reflect the exposure of 336 adult patients with type 2 diabetes to LYUMJEV with a mean exposure duration of 26 weeks [see Clinical Studies (14.3)]. The mean age was 60 years, the mean duration of diabetes was 16 years, 55% were male, 69% were White, 4% were Black or African American, and 24% were Hispanic. The mean BMI was 32.1 kg/m2 and the mean HbA1c at baseline was 7.3%.

The data in Table 3 reflect the exposure of 215 adult patients with type 1 diabetes to LYUMJEV via CSII administration with a mean exposure duration of 16 weeks [see Clinical Studies (14.4)]. The mean age was 48 years, the mean duration of diabetes was 26 years, 44% were male, 94% were White, 3% were Black or African American, and 8% were Hispanic. The mean BMI was 27.0 kg/m2 and the mean HbA1c at baseline was 7.6%.

Common adverse reactions, excluding hypoglycemia, were defined as events that occurred in ≥5% and at the same rate or greater for LYUMJEV-treated patients than HUMALOG-treated patients.

Table 1. Adverse Reactions That Occurred in ≥5% of LYUMJEV-Treated Adult Patients with Type 1 Diabetes
	Mealtime LYUMJEV + basal insulin (N=451) %	Postmeal LYUMJEV + basal insulin (N=329) %
Nasopharyngitis	14.2	14.6

Table 2. Adverse Reactions That Occurred in ≥5% of LYUMJEV-Treated Adult Patients with Type 2 Diabetes
	Mealtime LYUMJEV + basal insulin (N=336) %
Nasopharyngitis	12.5
Upper Respiratory Tract Infection	7.4

Table 3. Adverse Reactions That Occurred in ≥5% of LYUMJEV-Treated Adult Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
	CSII LYUMJEV administration (N=215) %
Infusion site reaction	19.1
Infusion site pain	15.8
Nasopharyngitis	6.0

Adverse Reaction Database – Pediatric Patients with Type 1 Diabetes

The data in Table 4 reflect the exposure of 418 pediatric patients with type 1 diabetes to LYUMJEV with a mean exposure duration of 26 weeks [see Clinical Studies (14.5)]. The mean age was 12 years; 50% were male, 91% were White, 1% were Black or African American; and 24% of the US subpopulation in this trial were Hispanic. The mean BMI was 20.5 kg/m2, the mean duration of diabetes was 5 years, and the mean HbA1c at baseline was 7.8%. Common adverse reactions, excluding hypoglycemia, were defined as events that occurred in ≥5% and at the same rate or greater for LYUMJEV-treated patients than HUMALOG-treated patients.

Table 4. Adverse Reactions That Occurred in ≥5% of LYUMJEV-Treated Pediatric Patients with Type 1 Diabetes
	Mealtime LYUMJEV + basal insulin (N=280) %	Postmeal LYUMJEV + basal insulin (N=138) %
Nasopharyngitis	8.2	5.1
Upper Respiratory Tract Infection	5.4	1.4

Hypoglycemia

Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including LYUMJEV. The rates of reported hypoglycemia depend on the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. For these reasons, comparing rates of hypoglycemia in clinical trials for LYUMJEV with the incidence of hypoglycemia for other products may be misleading and also may not be representative of hypoglycemia rates that occur in clinical practice.

Incidence rates for severe hypoglycemia in adults with type 1 and type 2 diabetes mellitus and pediatric patients with type 1 diabetes mellitus treated with LYUMJEV in clinical trials are shown in Table 5 [see Clinical Studies (14)].

Table 5. Proportion of Patients with Type 1 Diabetes and Type 2 Diabetes Who Experienced at Least One Episode of Severe Hypoglycemia in Adult and Pediatric Clinical Trials
a Severe hypoglycemia: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions
	PRONTO-T1D (Adult Type 1)		PRONTO-T2D (Adult Type 2)	PRONTO-Pump-2 (Adult Type 1 CSII)	PRONTO-Peds (Pediatric Type 1)
	Mealtime LYUMJEV + basal insulin (N=451) %	Postmeal LYUMJEV + basal insulin (N=329) %	Mealtime LYUMJEV + basal insulin (N=336) %	LYUMJEV (N=215) %	Mealtime LYUMJEV + basal insulin (N=280) %	Postmeal LYUMJEV + basal insulin (N=298) %
Severe hypoglycemiaa	5.5	4.6	0.9	1.4	1.1	0

Allergic Reactions

Severe, life-threatening, generalized allergy, including anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, and shock may occur with any insulin, including LYUMJEV, and may be life threatening. Generalized hypersensitivity reactions such as skin rashes and hypersensitivity were reported in adult patients treated with LYUMJEV: eczema (0.4%), rash (0.4%), dermatitis (0.3%), hypersensitivity (0.2%), and pruritus (0.2%).

Generalized hypersensitivity reactions reported in more than 1 pediatric patient treated with LYUMJEV included: rhinitis (0.7%), dermatitis (0.7%), rash (0.5%), and hypersensitivity (0.5%).

Lipodystrophy

Administration of insulin, including LYUMJEV, has resulted in lipohypertrophy (enlargement or thickening of tissue) and lipoatrophy (depression in the skin). Lipodystrophy was reported in 0.2% of adult and pediatric patients treated with LYUMJEV [see Dosage and Administration (2.2)].

Injection/Infusion Site Reactions

Injection or infusion site reactions can occur with insulin therapy. With LYUMJEV, adult and pediatric patients have experienced rash, redness, inflammation, pain, bruising, or itching at the site of LYUMJEV injection or infusion. LYUMJEV contains treprostinil sodium and sodium citrate dihydrate as inactive ingredients [see Description (11)] which have been associated with infusion and injection site reactions with other non-insulin products.

Subcutaneous Injection Site-Related Reactions:

In studies PRONTO-T1D and PRONTO-T2D, injection site-related reactions occurred in 2.7% of adult patients treated with LYUMJEV (mild in 2.2% and moderate in 0.5%). with <0.1% of patients discontinuing from treatment due to injection site-related reactions.

In Study PRONTO-Peds, injection site-related reactions occurred in 6.2% of pediatric patients treated with LYUMJEV (mild in 5.7% and moderate in 0.5%), with <0.5% of patients discontinuing from treatment due to injection site-related reactions.

Continuous Subcutaneous Insulin Infusion (CSII) Site-Related Reactions:

In Study PRONTO-Pump-2, infusion site-related reactions were reported in 37.7% of adult patients treated with LYUMJEV (mild in 27.9%, moderate in 7.9%, and severe in 1.9%), with 3.3% of patients discontinuing from treatment due to infusion site-related reactions. See Table 4.

Weight Gain

Weight gain can occur with insulin therapy, including LYUMJEV, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria. Adult patients with type 1 diabetes treated with LYUMJEV gained an average of 0.6 kg and patients with type 2 diabetes treated with LYUMJEV gained an average of 1.5 kg.

Peripheral Edema

Insulin, including LYUMJEV, may cause sodium retention and edema, particularly if previous poor metabolic control is improved by intensified insulin therapy. Peripheral edema occurred in 0.2% of adult patients treated with LYUMJEV.

6.2 Postmarketing Experience

The following additional adverse reactions have been identified during post-approval use of insulin lispro. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Localized cutaneous amyloidosis at the injection site has occurred with insulin use. Hyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site.

7. Drug Interactions

Table 6 includes clinically significant drug interactions with LYUMJEV.

Table 6. Clinically Significant Drug Interactions with LYUMJEV
Drugs That May Increase the Risk of Hypoglycemia
Drugs:	Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.
Intervention:	Dose reductions and increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.
Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV
Drugs:	Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.
Intervention:	Dose increases and increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.
Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LYUMJEV
Drugs:	Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.
Intervention:	Dose adjustment and increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.
Drugs That May Blunt Signs and Symptoms of Hypoglycemia
Drugs:	Beta-blockers, clonidine, guanethidine, and reserpine.
Intervention:	Increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.

8. Use In Specific Populations

8.1 Pregnancy

Risk Summary

Published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations). Pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. No adverse effects on embryo/fetal viability or morphology were observed in offspring of rats exposed to insulin lispro at a dose approximately 3 times the human subcutaneous dose of 1 unit insulin lispro/kg/day. No adverse effects on embryo/fetal development were observed in offspring of rabbits exposed to insulin lispro at doses up to approximately 0.2 times the human subcutaneous dose of 1 unit/kg/day (see Data).

The estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes with a HbA1c>7 and has been reported to be as high as 20% to 25% in women with a HbA1c>10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-associated Maternal and/or Embryo-Fetal Risk

Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

Data

Human Data

Published data from retrospective studies and meta-analyses do not report an association with insulin lispro and major birth defects, or adverse maternal or fetal outcomes when insulin lispro is used during pregnancy. However, these studies cannot definitely establish or exclude the absence of any risk because of methodological limitations including small sample size, selection bias, confounding by unmeasured factors, and some lacking comparator groups.

Animal Data

Animal reproduction studies have not been performed with LYUMJEV. However, subcutaneous reproduction and teratology studies have been conducted with insulin lispro. In a combined fertility and embryo-fetal development study, female rats were given subcutaneous insulin lispro injections of 1, 5, and 20 units/kg/day (0.2, 0.8, and 3 times the human subcutaneous dose of 1 unit insulin lispro/kg/day, based on units/body surface area, respectively) from 2 weeks prior to cohabitation through Gestation Day 19. There were no adverse effects on female fertility, implantation, or fetal viability and morphology. However, fetal growth retardation was produced at the 20 units/kg/day-dose as indicated by decreased fetal weight and an increased incidence of fetal runts/litter.

In an embryo-fetal development study in pregnant rabbits, insulin lispro doses of 0.1, 0.25, and 0.75 unit/kg/day (0.03, 0.08, and 0.2 times the human subcutaneous dose of 1 unit insulin lispro/kg/day, based on units/body surface area, respectively) were injected subcutaneously on Gestation Days 7 through 19. There were no adverse effects on fetal viability, weight, and morphology at any dose.

8.2 Lactation

Risk Summary

Available data from published literature suggests that exogenous human insulin products, including insulin lispro, are transferred into human milk. There are no adverse reactions reported in breastfed infants in the literature. There are no data on the effects of exogenous human insulin products, including insulin lispro, on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for insulin, any potential adverse effects on the breastfed child from LYUMJEV or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of LYUMJEV to improve glycemic control in pediatric patients with diabetes mellitus have been established. Use of LYUMJEV for this indication is supported by evidence from an adequate and well-controlled study in 716 pediatric patients with type 1 diabetes mellitus aged 1 year and older, and from studies in adult and pediatric patients with diabetes mellitus [see Clinical Pharmacology (12.3) and Clinical Studies (14.5)].

LYUMJEV-treated pediatric patients reported a higher incidence of subcutaneous injection site-related reactions compared to LYUMJEV-treated adults [see Adverse Reactions (6.1)]. It is expected that LYUMJEV-treated pediatric patients who receive continuous subcutaneous insulin infusion (CSII) are more likely to have infusion site-related adverse reactions than those who receive subcutaneous injections [see Adverse Reactions (6.1)]. Monitor injection and infusion sites closely when initiating therapy with LYUMJEV in pediatric patients. If persistent injection or infusion site reactions occur, discontinue LYUMJEV and initiate therapy with an alternative insulin.

8.5 Geriatric Use

Of the total number of LYUMJEV-treated patients in clinical studies for type 1 or type 2 diabetes (PRONTO-T1D and PRONTO-T2D, respectively), 17% (187/1,116) were 65 years of age and older, while 2% (18/1,116) were 75 years of age and older [see Clinical Studies (14.2, 14.3)].

No overall differences in safety or effectiveness of LYUMJEV have been observed between patients 65 years of age and older and younger adult patients.

8.6 Renal Impairment

Patients with renal impairment may be at increased risk of hypoglycemia and may require more frequent LYUMJEV dose adjustment and more frequent glucose monitoring [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].

8.7 Hepatic Impairment

Patients with hepatic impairment may be at increased risk of hypoglycemia and may require more frequent LYUMJEV dose adjustment and more frequent glucose monitoring [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].

10. Overdosage

Excess insulin administration may cause hypoglycemia and hypokalemia [see Warnings and Precautions (5.3, 5.5)]. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise, may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.

11. Lyumjev Description

Insulin lispro-aabc is a rapid-acting human insulin analog used to lower blood glucose. Insulin lispro-aabc is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Insulin lispro-aabc differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C257H383N65O77S6 and a molecular weight of 5808 daltons, both identical to that of human insulin.

Insulin lispro-aabc has the following primary structure:

LYUMJEV (insulin lispro-aabc) injection is a sterile, aqueous, clear, and colorless solution for subcutaneous or intravenous administration. Each mL of LYUMJEV U-100 contains 100 units of insulin lispro-aabc and the inactive ingredients: glycerol (12.1 mg), magnesium chloride hexahydrate (1.02 mg), metacresol (3.15 mg), sodium citrate dihydrate (4.41 mg), treprostinil sodium (1.06 mcg), zinc oxide (content adjusted to provide 39 mcg zinc ion), and Water for Injection, USP.

Each mL of LYUMJEV U-200 contains 200 units of insulin lispro-aabc and the inactive ingredients: glycerol (12.1 mg), magnesium chloride hexahydrate (1.02 mg), metacresol (3.15 mg), sodium citrate dihydrate (4.41 mg), treprostinil sodium (1.06 mcg), zinc oxide (content adjusted to provide 52 mcg zinc ion), and Water for Injection, USP.

Hydrochloric acid and/or sodium hydroxide may be added to adjust the pH. LYUMJEV has a pH of 7.0 to 7.8.

12. Lyumjev - Clinical Pharmacology

12.1 Mechanism of Action

The primary activity of LYUMJEV is the regulation of glucose metabolism. Insulins, including insulin lispro-aabc, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

12.2 Pharmacodynamics

The time course of insulin action (i.e., glucose lowering) may vary considerably in different individuals or within the same individual. The average pharmacodynamic profile [i.e., glucose lowering effect measured as glucose infusion rate (GIR) in a euglycemic clamp study] for subcutaneous administration of 7, 15, and 30 units of LYUMJEV in 42 healthy subjects is shown in Figure 1 and key characteristics of the timing of the effect are described in Table 7 below.

Figure 1. Mean Insulin Effect Over Time After Subcutaneous Administration of 7, 15, and 30 units of LYUMJEV in Healthy Subjects.

Table 7. Timing of Insulin Effect (i.e., Mean Pharmacodynamic Effect) After Subcutaneous Administration of 7, 15, and 30 Units of LYUMJEV in Healthy Subjects (N=42) and Corresponding to the Data Shown in Figure 1
Parameter for Insulin Effect	LYUMJEV 7 units	LYUMJEV 15 units	LYUMJEV 30 units
Time to first measurable effect	~17 minutes	~17 minutes	~15 minutes
Time to peak effect	~120 minutes	~138 minutes	~174 minutes
Time for effect to return to baseline	~4.6 hours	~6.2 hours	~7.3 hours

On average, the pharmacodynamic effects of LYUMJEV, measured as area under the glucose infusion rate-time curve (AUCGIR), was 1080 mg/kg, 1860 mg/kg, and 3030 mg/kg following administration of 7, 15, and 30 units of LYUMJEV in healthy subjects.

Similar pharmacodynamic profiles were observed in separate studies conducted in 40 patients with type 1 diabetes and 38 patients with type 2 diabetes given LYUMJEV subcutaneously as a single 15 unit dose.

The onset and total glucose lowering were similar when LYUMJEV was administered in the abdomen, deltoid, or thigh. The day-to-day variability [percent coefficient of variation (CV%)] within subjects in the glucose-lowering-effect of LYUMJEV was 24% for the early glucose lowering (AUCGIR, 0-1h), 27% for the total glucose lowering (AUCGIR, 0-10h), and 19% for maximum glucose lowering effect (GIRmax).

Postprandial Glucose Lowering

When given at the start of a meal or 20 minutes after the start of the meal, LYUMJEV reduced postprandial glucose during a standardized test meal over the complete 5-hour period [change from premeal AUC(0-5h)] in patients with type 1 or type 2 diabetes.

The maximum and total glucose lowering were comparable for a single 15 unit dose of LYUMJEV 200 units/mL or LYUMJEV 100 units/mL when administered subcutaneously to healthy subjects. The insulin time action profile with LYUMJEV 200 units/mL was the same as observed with LYUMJEV 100 units/mL.

12.3 Pharmacokinetics

Absorption

Absorption of insulin lispro-aabc was evaluated in healthy subjects (see Figure 2) and patients with diabetes following subcutaneous injection of LYUMJEV.

Insulin lispro-aabc appeared in circulation approximately 1 minute after injection of LYUMJEV.
Time to 50% maximum insulin lispro-aabc concentration was 13 minutes.
Time to maximum insulin lispro-aabc concentration was achieved at 57 minutes.

In healthy subjects, the day-to-day variability [CV%] within subjects of LYUMJEV was 10% for total exposure (AUC, 0-10h) and 16% for maximum insulin lispro-aabc concentration (Cmax).

Figure 2. Mean Serum Insulin Lispro-aabc After Subcutaneous Injection of LYUMJEV (15 unit dose) in Healthy Subjects

The absolute bioavailability of insulin lispro-aabc after subcutaneous administration of LYUMJEV in the abdomen, deltoid, and thigh was approximately 65%. The rate of absorption of insulin lispro-aabc is maintained regardless of injection site. Maximum concentration and time to maximum concentration were comparable for the abdomen and upper arm regions; time to maximum concentration was longer and maximum concentration was lower for the thigh.

Total insulin lispro-aabc exposure and maximum insulin lispro-aabc concentration increased proportionally with increasing subcutaneous doses of LYUMJEV within the therapeutic dose range.

The results of a study in healthy subjects demonstrated that LYUMJEV 200 units/mL is bioequivalent to LYUMJEV 100 units/mL following administration of a single 15 unit dose for the area under the serum insulin lispro-aabc concentration-time curve from time zero to infinity and maximum insulin lispro-aabc concentration. The rate of insulin lispro-aabc absorption after administration of LYUMJEV 200 units/mL was similar as observed with LYUMJEV 100 units/mL.

Distribution

Following a 15 unit intravenous bolus injection of LYUMJEV in healthy subjects, the geometric mean (CV%) volume of distribution of insulin lispro-aabc (Vd) was 34 L (30%).

Elimination

Following a 15 unit intravenous bolus injection of LYUMJEV in healthy subjects, the geometric mean (CV%) clearance of insulin lispro-aabc was 32 L/hour (22%) and the median half-life of insulin lispro-aabc was 44 minutes.

Specific Populations

Age, biological sex, and race did not affect the pharmacokinetics and pharmacodynamics of LYUMJEV.

Patients with Renal and Hepatic Impairment

Renal and hepatic impairment is not known to impact the pharmacokinetics of insulin lispro-aabc. Insulin requirements may be reduced in the presence of renal or hepatic impairment.

12.6 Immunogenicity

The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of insulin lispro-aabc or of other insulin lispro products.

In a 26-week trial in adult patients with type 1 diabetes (Study PRONTO-T1D) [see Clinical Studies (14.2)], 49% of LYUMJEV-treated patients were anti-drug (insulin lispro-aabc) antibody (ADA)-positive at baseline, 91% of whom had cross-reactive antibodies with native insulin. During this 26-week period in this trial, 33% of LYUMJEV-treated patients had treatment-emergent ADA post-baseline (i.e., either new ADA or a 57% increase in assay signal over baseline), 75% of whom had cross-reactive antibodies with native insulin.

In a 26-week trial in adult patients with type 2 diabetes (Study PROTO-T2D) [see Clinical Studies (14.3)], 35% of LYUMJEV-treated patients were ADA-positive at baseline, 81% of whom had cross-reactive antibodies with native insulin. During this 26-week period in this trial, 31% of LYUMJEV-treated patients had treatment-emergent ADA post-baseline (i.e., either new ADA or a 57% increase in assay signal over baseline), 68% of whom had cross-reactive antibodies with native insulin.

In a 26-week trial in pediatric patients with type 1 diabetes (Study-PRONTO-PEDS) [see Clinical Studies (14.5)], 73% of LYUMJEV-treated patients were ADA-positive at baseline. Of these ADA-positive patients, 97% had cross-reactive antibodies with native insulin. During this 26-week period in this trial, 31% of LYUMJEV-treated patients had treatment-emergent ADA post-baseline (i.e., either new ADA or a 57% increase in assay signal over baseline). Of these treatment-emergent ADA-positive patients, 84% had cross-reactive antibodies with native insulin.

In these clinical trials, there were no identified clinically significant effects of ADA on safety or effectiveness (measured by HbA1c) of LYUMJEV over the treatment duration of 26-weeks.

13. Nonclinical Toxicology

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In Fischer 344 rats, a 12-month repeat-dose toxicity study was conducted with insulin lispro at subcutaneous doses of 20 and 200 units/kg/day (approximately 3 and 32 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area). Insulin lispro did not produce important target organ toxicity including mammary tumors at any dose.

Insulin lispro was not mutagenic in the following genetic toxicity assays: bacterial mutation, unscheduled DNA synthesis, mouse lymphoma, chromosomal aberration, and micronucleus assays.

Male fertility was not compromised when male rats given subcutaneous insulin lispro injections of 5 and 20 units/kg/day (0.8 and 3 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area) for 6 months were mated with untreated female rats. In a combined fertility, perinatal, and postnatal study in male and female rats given 1, 5, and 20 units/kg/day subcutaneously (0.2, 0.8, and 3 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area), mating and fertility were not adversely affected in either gender at any dose.

14. Clinical Studies

14.1 Overview of Clinical Studies

The effectiveness of LYUMJEV was evaluated in:

Two randomized, active controlled trials of 26 weeks in adults with type 1 diabetes (N=780) or type 2 diabetes (N=336) (PRONTO-T1D and PRONTO-T2D, respectively) [see Clinical Studies (14.2, 14.3)].
A randomized, active controlled 16-week trial in adults with type 1 diabetes using continuous subcutaneous insulin infusion (N=432) (PRONTO-Pump-2) [see Clinical Studies (14.4)].
A randomized, active controlled 26-week trial in pediatric patients with type 1 diabetes (N=716) (PRONTO-Peds) [see Clinical Studies (14.5)].

14.2 Adults with Type 1 Diabetes

PRONTO-T1D (NCT03214367) was a 26 week, randomized (4:4:3), active controlled, treat-to-target, multinational trial that evaluated the efficacy of LYUMJEV in 1222 adult patients with type 1 diabetes. Patients were randomized to either blinded mealtime LYUMJEV (N=451), blinded mealtime HUMALOG (N=442), or open-label postmeal LYUMJEV (N=329), all in combination with either insulin glargine or insulin degludec. Mealtime LYUMJEV or HUMALOG was injected 0 to 2 minutes before the meal and postmeal LYUMJEV was injected 20 minutes after the start of the meal.

Patients had a mean age of 44 years; mean duration of diabetes of 19 years; 56% were male; race: 77% White, 19% Asian, and 2% Black or African American. Eight percent of the randomized patients were Hispanic. The mean BMI was 26.6 kg/m2.

At week 26, treatment with mealtime LYUMJEV provided a mean reduction in HbA1c that met the pre-specified non-inferiority margin (0.4%) (see Table 8). In addition, postmeal LYUMJEV met the prespecified non-inferiority margin (0.4%) compared to mealtime HUMALOG. Insulin doses were similar in all treatment groups at baseline and at 26 weeks.

Table 8. Results from Study PRONTO-T1D: 26 Week Trial of Mealtime LYUMJEV and Postmeal LYUMJEV compared with Mealtime HUMALOG, all in Combination with Basal Insulin in Adults with Type 1 Diabetes
a Analysis population: all randomized subjects regardless of adherence to treatment or availability of post-baseline assessment. Missing data at Week 26 were imputed by return to baseline approach. At week 26, primary efficacy assessment was missing for 3.8%, 4.8%, and 5.2% of subjects, for mealtime LYUMJEV, mealtime HUMALOG, and postmeal LYUMJEV, respectively.
b Least-squares (LS) mean from ANCOVA adjusted for baseline value and other stratification factors.
c Tested for non-inferiority.
	Mealtime LYUMJEV + basal insulin	Mealtime HUMALOG + basal insulin	Postmeal LYUMJEV + basal insulin
Number of randomized subjects (N)	451	442	329
HbA1c (%) (mean)a
Baseline	7.3	7.3	7.4
Adjusted mean change from baselineb	-0.12	-0.04	0.1
Estimated treatment difference versus HUMALOG [95% CI]	-0.08 [-0.16, 0.00]c		0.14 [0.05, 0.22]

14.3 Adults with Type 2 Diabetes

PRONTO-T2D (NCT03214380) was a 26-week, randomized (1:1), active controlled, treat-to-target, multinational trial that evaluated the efficacy of LYUMJEV in 673 adult patients with type 2 diabetes who at study entry were on multiple daily injections with either basal insulin and at least one prandial insulin injection or premixed insulin with at least two injections daily. Patients may also have been treated with up to three oral anti-diabetic medications (OAMs) in addition to insulin. Patients were allowed to continue on metformin and/or a SGLT2 inhibitor and were randomized to either mealtime LYUMJEV (N=336) or to mealtime HUMALOG (N=337), both in combination with insulin glargine or insulin degludec in a basal-bolus regimen. Mealtime LYUMJEV or mealtime HUMALOG was injected 0-2 minutes before the meal.

Patients had a mean age of 61 years; mean duration of diabetes of 17 years; 53% were male; race: 69% White, 24% Asian, and 5% Black or African American. Twenty-three percent of the randomized patients were Hispanic. The mean BMI was 32.3 kg/m2.

At week 26, treatment with mealtime LYUMJEV provided a mean reduction of HbA1c from baseline that met the pre-specified non-inferiority margin (0.4%) compared to mealtime HUMALOG (see Table 9). Insulin doses were similar in both treatment groups at baseline and at 26 weeks.

Table 9. Results from Study PRONTO-T2D: 26 Week Trial of Mealtime LYUMJEV Compared with Mealtime HUMALOG, both in Combination with Basal Insulin in Adults with Type 2 Diabetes
a Analysis population: all randomized subjects regardless of adherence to treatment or availability of post-baseline assessment. Missing data at Week 26 were imputed by return to baseline approach. At week 26, primary efficacy assessment was missing for 4.8% of subjects for mealtime LYUMJEV and for 4.5% mealtime HUMALOG.
b Least-squares (LS) mean from ANCOVA adjusted for baseline value and other stratification factors.
c Tested for non-inferiority.
	Mealtime LYUMJEV + basal insulin	Mealtime HUMALOG + basal insulin
Number of randomized subjects (N)	336	337
HbA1c (%)a
Baseline mean	7.3	7.3
Adjusted mean change from baselineb	-0.36	-0.38
Estimated treatment difference versus HUMALOG [95% CI]c	0.03 [-0.08, 0.13]

14.4 Adults with Type 1 Diabetes – Continuous Subcutaneous Insulin Infusion (CSII)

PRONTO-Pump-2 (NCT03830281) was a 16 week randomized (1:1), active controlled, treat-to-target, multinational trial that evaluated the efficacy of LYUMJEV in 432 adult patients with type 1 diabetes currently using continuous subcutaneous insulin infusion. Patients were randomized to either blinded LYUMJEV (N=215) or blinded HUMALOG (N= 217). Mealtime LYUMJEV or HUMALOG boluses were initiated 0 to 2 minutes before the meal.

Patients had a mean age of 46 years; mean duration of diabetes of 26 years; 45% were male; race: 95% White, 3% Black or African American, and 0.5% Asian. Eight percent of the randomized patients were Hispanic. The mean BMI was 27.1 kg/m2.

At week 16, treatment with LYUMJEV provided a mean reduction in HbA1c that met the pre-specified non-inferiority margin (0.4%) compared to mealtime HUMALOG (see Table 10). Total daily insulin doses were similar for both treatment groups at baseline and at 16 weeks.

Table 10. Results from Study PRONTO-Pump-2: 16 Week Trial of LYUMJEV compared with HUMALOG in Adults with Type 1 Diabetes
a Analysis population: all randomized subjects regardless of adherence to treatment or availability of post-baseline assessment. Missing data at Week 16 were imputed by return to baseline approach. At week 16, primary efficacy assessment was missing for 7% and 4.6% of subjects, for LYUMJEV and HUMALOG, respectively.
b Least-squares (LS) mean from ANCOVA adjusted for baseline value and other stratification factors.
c Tested for non-inferiority.
	LYUMJEV	HUMALOG
Number of randomized subjects (N)	215	217
HbA1c (%)a
Baseline mean	7.6	7.5
Adjusted mean change from baselineb	-0.06	-0.09
Estimated treatment difference versus HUMALOG [95% CI]c	0.03 [-0.05, 0.11]

14.5 Pediatric Patients with Type 1 Diabetes

PRONTO-Peds (NCT03740919) was a 26-week, randomized (2:2:1), active controlled, treat-to-target, multinational trial that evaluated the efficacy of LYUMJEV in 716 pediatric patients with type 1 diabetes. Patients were randomized to either blinded mealtime LYUMJEV (N=280), blinded mealtime HUMALOG (N=298), or open-label postmeal LYUMJEV (N=138), all in combination with basal insulin (insulin glargine, insulin degludec or insulin detemir). Mealtime LYUMJEV or HUMALOG was injected 0 to 2 minutes before the meal and postmeal LYUMJEV was injected within 20 minutes after the start of the meal.

Patients had a mean age of 12 years (3-17 years); 51% were male; race: 89% White, 6% Asian, and 2% Black or African American. In the U.S. subpopulation in this trial, 24% of the randomized patients were Hispanic. The mean BMI was 20.4 kg/m2 and the mean duration of diabetes was 5 years.

At week 26, treatment with mealtime LYUMJEV provided a mean change in HbA1c that met the pre-specified non-inferiority margin (0.4%) (see Table 11). In addition, postmeal LYUMJEV met the prespecified non-inferiority margin (0.4%) compared to mealtime HUMALOG. Insulin doses were similar in all treatment groups at baseline and at 26 weeks.

Table 11. Results from Study PRONTO-Peds: 26 Week Trial of Mealtime LYUMJEV and Postmeal LYUMJEV compared with Mealtime HUMALOG, all in Combination with Basal Insulin in Pediatric Patients with Type 1 Diabetes
a Analysis population: all randomized subjects regardless of adherence to treatment or availability of post-baseline assessment. Missing data at Week 26 were imputed by return to baseline approach. At week 26, primary efficacy assessment was missing for 5.4%, 7.1%, and 5.1% of subjects, for mealtime LYUMJEV, mealtime HUMALOG, and postmeal LYUMJEV, respectively.
b Least-squares (LS) mean from ANCOVA adjusted for baseline value and other stratification factors.
c Tested for non-inferiority.
	Mealtime LYUMJEV + basal insulin	Mealtime HUMALOG + basal insulin	Postmeal LYUMJEV + basal insulin
Number of randomized subjects (N)	280	298	138
HbA1c (%) (mean) a
Baseline	7.8	7.8	7.8
Adjusted mean change from baselineb	0.06	0.06	0.06
Estimated treatment difference versus HUMALOG [95% CI]c	-0.01 [-0.15, 0.14]		-0.00 [-0.18, 0.18]

16. How is Lyumjev supplied

16.1 How Supplied

LYUMJEV (insulin lispro-aabc) injection is a clear and colorless solution available as shown in Table 12.

Table 12. How Supplied
a 3 mL cartridge is for use in Eli Lilly and Company's HumaPen® Luxura® HD insulin delivery device. Patients need to check their device manual to determine if the LYUMJEV cartridge is compatible for use in other devices.
b Tempo Pen contains a component that allows for data connectivity when used with a compatible transmitter.
LYUMJEV	NDC Number	Concentration	Total Units in Presentation	Dose Increment	Package Size
U-100 multiple-dose 10 mL vial	0002-7728-01	100 units/mL	1,000 units	n/a	1 vial
U-100 single-patient-use 3 mL cartridgea	0002-7726-05	100 units/mL	300 units	n/a	5 cartridges
U-100 single-patient-use 3 mL KwikPen	0002-8207-05	100 units/mL	300 units	1 unit	5 pens
U-100 single-patient-use 3 mL Junior KwikPen	0002-8351-05	100 units/mL	300 units	0.5 unit	5 pens
U-100 single-patient-use 3 mL Tempo Penb	0002-8235-05	100 units/mL	300 units	1 unit	5 pens
U-200 single-patient-use 3 mL KwikPen	0002-8228-27	200 units/mL	600 units	1 unit	2 pens

16.2 Storage and Handling

Dispense in the original sealed carton with the enclosed Instructions for Use.
Refrigerate unopened LYUMJEV vials, pens, and cartridges between 36°F to 46°F (2°C to 8°C) until time of use and keep in the original carton to protect from light. Do not freeze or use LYUMJEV if it has been frozen. Do not expose to direct heat. Discard opened or unopened LYUMJEV vials, pens, and cartridges stored at room temperature below 86°F (30°C) after 28 days.

The storage conditions for vials, pens, and cartridges are summarized in Table 13.

Table 13. Storage Conditions for Vials, Pens, and Cartridges
a In-use (opened) vials, whether or not refrigerated, must be used within 28 days.
b When stored at room temperature, LYUMJEV can only be used for a total of 28 days including both not in-use (unopened) and in-use (opened) storage time.
LYUMJEV Presentation	Not In-use (Unopened)		In-use (Opened)
	Room Temperature (below 86°F [30°C])	Refrigerated (36°F to 46°F [2°C to 8°C])	Room Temperature (below 86°F [30°C])	Refrigerated (36°F to 46°F [2°C to 8°C])
10 mL viala,b	28 days	Until expiration date	28 days	28 days
3 mL cartridgeb	28 days	Until expiration date	28 days	Do not refrigerate
3 mL LYUMJEV KwikPen (U-100 and U-200)b	28 days	Until expiration date	28 days	Do not refrigerate
3 mL LYUMJEV Junior KwikPenb	28 days	Until expiration date	28 days	Do not refrigerate
3 mL LYUMJEV Tempo Penb	28 days	Until expiration date	28 days	Do not refrigerate

Storage of LYUMJEV in Insulin Pump

Change the LYUMJEV U-100 in the pump reservoir at least every 9 days, or according to the pump user manual, whichever is shorter, or after exposure to temperatures that exceed 98.6°F (37°C).

Storage of LYUMJEV in Intravenous Infusion Fluids

Diluted LYUMJEV may be stored for up to 4 days when refrigerated at 36°F to 46°F (2°C to 8°C) until time of use. The same solution may be stored up to 12 hours at room temperature at 68°F to 77°F (20°C to 25°C) [see Dosage and Administration (2.2)].

17. Patient Counseling Information

Advise the patient to read the FDA-Approved Patient Labeling (Patient Information and Instructions for Use).

Never Share a LYUMJEV Prefilled Pen, Cartridge, or Syringe Between Patients

Advise patients that they must never share a LYUMJEV prefilled pen or cartridge with another person, even if the needle is changed. Advise patients using LYUMJEV vials not to share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens [see Warnings and Precautions (5.1)].

Hyperglycemia or Hypoglycemia

Inform patients that hypoglycemia is the most common adverse reaction with insulin. Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia, especially at initiation of LYUMJEV therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia.

Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery [see Warnings and Precautions (5.3)].

Advise patients that changes in insulin regimen can predispose to hyperglycemia or hypoglycemia and that changes in insulin regimen should be made under close medical supervision [see Warnings and Precautions (5.2)].

Hypoglycemia due to Medication Errors

Instruct patients to always check the insulin label before each injection to avoid mix-ups between insulin products.

Inform patients that LYUMJEV U-200 contains 2 times as much insulin per mL as LYUMJEV U-100. The LYUMJEV U-200 KwikPen dose window shows the number of units of LYUMJEV U-200 to be injected so no dose conversion is required [see Dosage and Administration (2.1)].

Instruct patients to not transfer LYUMJEV U-200 from the LYUMJEV U-200 KwikPen to a syringe [see Warnings and Precautions (5.4)].

Hypersensitivity Reactions

Advise patients that hypersensitivity reactions have occurred with LYUMJEV. Inform patients on the symptoms of hypersensitivity reactions [see Warnings and Precautions (5.6)].

Instructions for Patients Using Continuous Subcutaneous Infusion (Insulin Pump)

Do not use LYUMJEV U-200 in an insulin pump.
Train patients in intensive insulin therapy with multiple injections and in the function of their pump and pump accessories.
Instruct patients to follow healthcare provider recommendations when setting pump basal rates and bolus settings.
Refer to the continuous subcutaneous infusion pump user manual to see if LYUMJEV can be used with the pump. See recommended reservoir and infusion sets in the insulin pump user manual.
Instruct patients to replace insulin in the reservoir at least every 9 days, or according to the pump user manual whichever is shorter. By following this schedule, patients avoid insulin degradation, infusion set occlusion, and loss of the insulin preservative.
Instruct patients to discard insulin exposed to temperatures higher than 98.6°F (37°C).
Instruct patients to inform healthcare provider and select a new site for infusion if infusion site becomes erythematous, pruritic, or thickened.
Instruct patients on the risk of rapid hyperglycemia and ketosis due to pump malfunction, infusion set occlusion, leakage, disconnection or kinking, and degraded insulin. Instruct patients on the risk of hypoglycemia from pump malfunction. If these problems cannot be promptly corrected, instruct patients to resume therapy with subcutaneous insulin injection and contact their healthcare provider [see Warnings and Precautions (5) and How Supplied/Storage and Handling (16.2)].

Eli Lilly and Company, Indianapolis, IN 46285, USA

US License No. 1891

LUM-0003-USPI-20221014

LYUMJEV PATIENT PACKAGE INSERT

This Patient Information has been approved by the U.S. Food and Drug Administration		Revised: October 2022
Patient Information LYUMJEV® (LOOM-jehv) (insulin lispro-aabc) injection, for subcutaneous or intravenous use
Do not share your LYUMJEV with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
What is LYUMJEV? LYUMJEV is a man-made fast-acting insulin used to control high blood sugar in adults and children with diabetes mellitus.
Do not take LYUMJEV if you: are having an episode of low blood sugar (hypoglycemia). have an allergy to insulin lispro-aabc or any of the ingredients in LYUMJEV. See the end of this Patient Information leaflet for a complete list of ingredients in LYUMJEV.
Before taking LYUMJEV, tell your healthcare provider about all of your medical conditions, including if you: have kidney or liver problems. take any other medicines, especially ones called thiazolidinediones (TZDs). have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with LYUMJEV. are pregnant or plan to become pregnant. Talk with your healthcare provider about the best way to control your blood sugar if you plan to become pregnant or while you are pregnant. are breastfeeding or plan to breastfeed. It is not known if LYUMJEV passes into your breast milk. You and your healthcare provider should decide if you will take LYUMJEV while you breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Before you start taking LYUMJEV, talk to your healthcare provider about low blood sugar and how to manage it.
How should I take LYUMJEV? Read the Instructions for Use that come with your LYUMJEV. Take LYUMJEV exactly as your healthcare provider tells you to. Your healthcare provider will tell you how much LYUMJEV to take and when to take it. LYUMJEV starts acting fast. Inject LYUMJEV at the beginning of a meal or within 20 minutes after you start eating a meal. Know the type and strength of insulin you take. Do not change the type or amount of insulin you take unless your healthcare provider tells you to. The amount of insulin and the best time for you to take your insulin may need to change if you take different types of insulin. Check your insulin label each time you give your injection to make sure you are using the correct insulin. Check your blood sugar levels. Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar level. LYUMJEV comes in U-100 (100 units/mL) and U-200 (200 units/mL) insulin strengths. LYUMJEV U-200 contains 2 times as much insulin (200 units/mL) in 1 mL as LYUMJEV U-100 (100 units/mL). LYUMJEV U-100 and LYUMJEV U-200 can be injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs, or upper arms. LYUMJEV U-100 can be given by continuous infusion under the skin (subcutaneously) through an insulin pump into an area of your body recommended in the instructions that come with your insulin pump. LYUMJEV U-200 cannot be given through an insulin pump. LYUMJEV U-100 can also be given in your vein (intravenously) by your healthcare provider. LYUMJEV U-200 cannot be given in your vein. Change (rotate) your injection sites within the area you choose with each dose to reduce your risk of getting pits in skin or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites. Do not use the exact same spot for each injection. Do not inject where the skin has pits, is thickened, or has lumps. Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin. If you miss a dose of LYUMJEV, monitor your blood sugar levels to decide if an insulin dose is needed. Continue with your regular dosing schedule at the next meal. LYUMJEV comes in a vial, single-patient-use prefilled pen, or in a cartridge. Do not use a syringe to remove LYUMJEV from your single-patient-use prefilled pen or cartridge.
Keep LYUMJEV and all medicines out of the reach of children.
Your dose of LYUMJEV may need to change because of: a change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or because of other medicines you take.
What should I avoid while taking LYUMJEV? While taking LYUMJEV do not: drive or operate heavy machinery, until you know how LYUMJEV affects you. drink alcohol or take other medicines that contain alcohol.
What are the possible side effects of LYUMJEV? LYUMJEV may cause serious side effects that can lead to death, including: low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include: dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, hunger, anxiety, irritability, or mood changes. low potassium in your blood (hypokalemia). serious allergic reactions (whole body allergic reaction). Get emergency medical help right away, if you have any of these symptoms of a severe allergic reaction: a rash over your whole body, trouble breathing, a fast heartbeat, swelling of your face, tongue, or throat, sweating, or feeling faint. heart failure. Taking certain diabetes pills called thiazolidinediones (TZDs) with LYUMJEV may cause heart failure in some people. This can happen even if you have never had heart failure or heart failure problems before. If you already have heart failure it may get worse while you take TZDs with LYUMJEV. Your healthcare provider should monitor you closely while you are taking TZDs with LYUMJEV. Tell your healthcare provider if you have any new or worse symptoms of heart failure including: shortness of breath, swelling of your ankles or feet, or sudden weight gain. Treatment with TZDs and LYUMJEV may need to be adjusted or stopped by your healthcare provider if you have new or worse heart failure. sudden onset of high blood sugar (hyperglycemia) and high amounts of ketones in the blood or urine (ketoacidosis) due to insulin pump problems. If LYUMEV is given through an insulin pump and the pump is not working the right way or in case of handling errors, you may not get the right amount of insulin, which can cause a sudden onset of high blood sugar and high amounts of ketones in the blood or urine.
Get emergency medical help if you have: trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue or throat, sweating, extreme drowsiness, dizziness, or confusion.
The most common side effects of LYUMJEV include:
low blood sugar (hypoglycemia) allergic reactions rash itching (pruritus)	thickening or pits at the injection or infusion site (lipodystrophy) weight gain
reactions or pain at the site of injection or at the site of infusion with insulin pump use (treprostinil sodium and sodium citrate dihydrate are inactive ingredients in LYUMJEV that have been known to cause reactions and pain at the infusion and injection sites in other non-insulin medicines)
These are not all the possible side effects of LYUMJEV. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of LYUMJEV. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not take LYUMJEV for a condition for which it was not prescribed. Do not give LYUMJEV to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about LYUMJEV that is written for health professionals.
What are the ingredients in LYUMJEV? Active ingredient: insulin lispro-aabc Inactive ingredients: glycerol, magnesium chloride hexahydrate, metacresol, sodium citrate dihydrate, treprostinil sodium, zinc oxide (zinc ion), and Water for Injection, USP
LYUMJEV® is a registered trademark of Eli Lilly and Company. Eli Lilly and Company Indianapolis, IN 46285, USA US License Number 1891 Copyright © 2020, 2022, Eli Lilly and Company. All rights reserved. For more information, go to www.lilly.com or call 1-800-545-5979.

LUM-0003-PPI-20221014

LYUMJEV VIAL U-100 INSTRUCTIONS FOR USE

Instructions for Use

LYUMJEV™ (LOOM-jehv)

(insulin lispro-aabc) injection

for subcutaneous use

(100 units/mL, 10 mL multiple-dose vial)

Read the Instructions for Use before you start taking LYUMJEV and each time you get a new vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

Do not share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.

Supplies needed to give your injection

a multiple-dose LYUMJEV vial
a U-100 insulin syringe and needle (Becton, Dickinson and Company syringes and needles recommended)
2 alcohol swabs
gauze (optional)
1 sharps container for throwing away used syringes and needles. See “Disposing of used syringes and needles” at the end of these instructions.

Preparing your LYUMJEV dose

Wash your hands with soap and water.
Check the LYUMJEV label to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
LYUMJEV should look clear and colorless. Do not use LYUMJEV if it is thick, cloudy, or colored, or if you see lumps or particles in it.
Do not use LYUMJEV past the expiration date printed on the label or 28 days after you first use it.
Always use a new syringe and needle for each injection to prevent infections and blocked needles.
Do not mix LYUMJEV U-100 with other insulins.

Step 1: If you are using a new vial, pull off the plastic protective cap, but do not remove the rubber stopper.
Step 2: Wipe the rubber stopper with an alcohol swab.
Step 3: Remove the needle shield from the syringe by pulling the needle shield straight off. Hold the syringe with the needle pointing up. Pull down on the plunger until the plunger tip reaches the line for the number of units for your prescribed dose.	(Example Dose: 20 units shown)
Step 4: Push the needle through the rubber stopper of the vial.
Step 5: Push the plunger all the way in. This puts air into the vial.
Step 6: Turn the vial and syringe upside down and slowly pull the plunger down until the plunger tip is a few units past the line for your prescribed dose.	(Example Dose: 20 units, plunger is shown at 24 units)
If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the top.
Step 7: Slowly push the plunger up until the plunger tip reaches the line for your prescribed dose. Check the syringe to make sure that you have the right dose.	(Example Dose: 20 units shown)
Step 8: Pull the syringe out of the rubber stopper of the vial.

Giving your LYUMJEV injection with a syringe

Inject your insulin exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you should pinch the skin before injecting.
LYUMJEV starts acting fast, so give your injection at the start of a meal or within 20 minutes after you start a meal.
Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
Do not use the exact same spot for each injection.
Do not inject where the skin has pits, is thickened, or has lumps.
Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.

Step 9: Choose your injection site. LYUMJEV is injected under the skin (subcutaneously) of your stomach area (abdomen), buttocks, upper legs, or upper arms. Wipe your skin with an alcohol swab, and let your skin dry before you inject your dose.
Step 10: Insert the needle into your skin.
Step 11: Push down on the plunger to inject your dose. The needle should stay in your skin for at least 5 seconds after pushing down on the plunger to make sure you have injected all of your insulin dose.
Step 12: Pull the needle out of your skin. If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab. Do not rub the area. Do not recap the needle. Recapping the needle can lead to a needle stick injury.

Giving your LYUMJEV using an insulin pump

If you have been prescribed an insulin pump, check the pump manufacturer's user manual to see if LYUMJEV can be used with the pump.
LYUMJEV should be given into an area of your body recommended in the instructions that come with your insulin pump.
Change LYUMJEV in the pump reservoir at least every 9 days or according to the pump user manual, whichever is shorter, even if you have not used all of the insulin.
Change (rotate) your insertion sites within the area you choose for each insertion to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the insertion sites. Do not insert into the exact same spot for each insertion. Do not insert where the skin has pits, is thickened, or has lumps. Do not insert where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
Call your healthcare provider and choose a new infusion site if the skin at the infusion site becomes red, itchy, or thickened.
Your healthcare provider should provide recommendations for appropriate pump basal and meal-time infusion rates. Call your healthcare provider if you have any questions about using the insulin pump.
Do not dilute or mix LYUMJEV with any other type of insulin in your insulin pump.
You should be trained on how to give insulin by injection and have an alternative insulin delivery system in case of pump failure.

Disposing of used syringes and needles

Put your used syringes and needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose syringes and needles in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:

–

made of a heavy-duty plastic,

–

can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,

–

upright and stable during use,

–

leak-resistant, and

–

properly labeled to warn of hazardous waste inside the container.
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used syringes and needles. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

How should I store LYUMJEV?

All not in-use (unopened) vials:

Store all not in-use (unopened) vials in the refrigerator at 36°F to 46°F (2°C to 8°C).
Do not freeze. Do not use if LYUMJEV has been frozen.
Keep away from direct heat and light.
Not in-use (unopened) vials can be used until the expiration date on the carton and label, if they have been stored in the refrigerator.
Not in-use (unopened) vials should be thrown away after 28 days, if they are stored at room temperature.

After vials have been in-use (opened):

Store in-use (opened) vials in the refrigerator or at room temperature below 86°F (30°C) for up to 28 days.
Keep vials away from direct heat and light.
Throw away all in-use (opened) vials after 28 days of use, even if there is insulin left in the vial.

LYUMJEV in an insulin pump:

Throw away LYUMJEV in the pump reservoir if it has been exposed to temperatures higher than 98.6°F (37°C).

Keep LYUMJEV vials, syringes, needles and all medicines out of the sight and reach of children.

If you have any questions or problems with your LYUMJEV, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help. For more information on LYUMJEV and insulin, go to www.lyumjev.com.

Scan this code to launch

www.lyumjev.com

Manufactured by:
Eli Lilly and Company
Indianapolis, IN 46285, USA
US License Number 1891

LYUMJEV™ is a trademark of Eli Lilly and Company.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Revised: August 2021
LUMVL-0002-IFU-20210813

LYUMJEV KWIKPEN U-100 INSTRUCTIONS FOR USE

Instructions for Use

LYUMJEV™ KwikPen®(LOOM-jehv)

(insulin lispro-aabc)

injection, for subcutaneous use

3 mL single-patient-use pen

100 units/mL

Read the Instructions for Use before you start taking LYUMJEV™ and each time you get another LYUMJEV KwikPen. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

Do not share your LYUMJEV KwikPen with other people, even if the needle has been changed. Do not reuse or share needles with other people. You may give other people a serious infection or get a serious infection from them.

LYUMJEV KwikPen (“Pen”) is a disposable single-patient-use prefilled pen containing 300 units of LYUMJEV.

Your healthcare provider will tell you how many units to give as your dose and how to inject your prescribed dose of insulin.
You can give yourself more than 1 dose from the Pen.
Each turn of the dose knob dials 1 unit of insulin. You can give from 1 to 60 units in a single injection.
If your dose is more than 60 units, you will need to give yourself more than 1 injection. Always check the number in the dose window to make sure you dialed the correct dose.
The plunger only moves a little with each injection, and you may not notice that it moves. The plunger will only reach the end of the cartridge when you have used all 300 units in the Pen.

People who are blind or have vision problems should not use the Pen without help from a person trained to use the Pen.

How to recognize your LYUMJEV KwikPen

Pen color:	Taupe
Dose Knob:	Blue, with raised ridges on side
Label:	Blue and white

Supplies needed to give your injection

LYUMJEV KwikPen, 100 units/mL
KwikPen compatible needle (Becton, Dickinson and Company Pen needles recommended)
Alcohol swab
Gauze (optional)

Preparing your Pen

Wash your hands with soap and water.
Check the Pen to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
Do not use your Pen past the expiration date printed on the label or for more than 28 days after you first start using the Pen.
Always use a new needle for each injection to help prevent infections and blocked needles.

Step 1: Pull the Pen cap straight off. – Do not remove the Pen label. Wipe the rubber seal with an alcohol swab.
Step 2: Check the liquid in the Pen. LYUMJEV should look clear and colorless. Do not use if it is cloudy, colored, or has particles or clumps in it.
Step 3: Select a new needle. Pull off the paper tab from the outer needle shield.
Step 4: Push the capped needle straight onto the Pen and twist the needle on until it is tight.
Step 5: Pull off the outer needle shield. Do not throw it away. Pull off the inner needle shield and throw it away.

Priming your Pen

Prime before each injection.

Priming your Pen means removing the air from the needle and cartridge that may collect during normal use and ensures that your Pen is working correctly.
If you do not prime before each injection, you may get too much or too little insulin.

Step 6:

To prime your Pen, turn the dose knob to select 2 units.

Step 7:

Hold your Pen with the needle pointing up. Tap the cartridge holder gently to collect air bubbles at the top.

Step 8:

Continue holding your Pen with the needle pointing up. Push the dose knob in until it stops and “0” is seen in the dose window. Hold the dose knob in and count to 5 slowly.

You should see insulin at the tip of the needle.

–: If you do not see insulin, repeat priming steps 6 to 8, but not more than 4 times.
–: If you still do not see insulin, change the needle and repeat priming steps 6 to 8.

Small air bubbles are normal and will not affect your dose.

Selecting your dose

You can give from 1 to 60 units in a single injection.
If your dose is more than 60 units, you will need to give more than 1 injection.

–

If you need help with dividing up your dose the right way, ask your healthcare provider.

–

Use a new needle for each injection and repeat the priming steps.

Step 9:

Turn the dose knob to select the number of units you need to inject. The dose indicator should line up with your dose.

–

The Pen dials 1 unit at a time.

–

The dose knob clicks as you turn it.

–

Do not dial your dose by counting the clicks. You may dial the wrong dose. This may lead to you getting too much insulin or not enough insulin.

–

The dose can be corrected by turning the dose knob in either direction until the correct dose lines up with the dose indicator.

–

The even numbers are printed on the dial. The example to the right shows 12 units in the dose window.

–

The odd numbers, after the number 1, are shown as full lines between the numbers. The example to the right shows 25 units in the dose window.
Always check the number in the dose window to make sure you have dialed the correct dose.

Example: 12 units shown in the dose window

Example: 25 units shown in the dose window

The Pen will not let you dial more than the number of units left in the Pen.
If you need to inject more than the number of units left in the Pen, you may either:

–

inject the amount left in your Pen and then use a new Pen to give the rest of your dose,
or

–

get a new Pen and inject the full dose.
It is normal to see a small amount of insulin left in the Pen that you cannot inject.

Giving your injection

Inject your insulin as your healthcare provider has shown you.
Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
Do not use the exact same spot for each injection.
Do not inject where the skin has pits, is thickened, or has lumps.
Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
Do not try to change your dose while injecting.

Step 10: Choose your injection site. LYUMJEV is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms. Wipe your skin with an alcohol swab, and let your skin dry before you inject your dose.
Step 11: Insert the needle into your skin. Push the dose knob all the way in.
Continue to hold the dose knob in and slowly count to 5 before removing the needle. Do not try to inject your insulin by turning the dose knob. You will not receive your insulin by turning the dose knob.
Step 12: Pull the needle out of your skin. – A drop of insulin at the needle tip is normal. It will not affect your dose. Check the number in the dose window. – If you see “0” in the dose window, you have received the full amount you dialed. – If you do not see “0” in the dose window, you did not receive your full dose. Do not redial. Insert the needle into your skin and finish your injection. – If you still do not think you received the full amount you dialed for your injection, do not start over or repeat that injection. Monitor your blood glucose as instructed by your healthcare provider. – If you normally need to give 2 injections for your full dose, be sure to give your second injection. The plunger only moves a little with each injection, and you may not notice that it moves. If you see blood after you take the needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. Do not rub the area.

After your injection

Step 13: Carefully replace the outer needle shield.
Step 14: Unscrew the capped needle and throw it away (see Disposing of Pens and needles section). Do not store the Pen with the needle attached to prevent leaking, blocking the needle, and air from entering the Pen.
Step 15: Replace the Pen cap by lining up the cap clip with the dose indicator and pushing straight on.

Disposing of Pens and needles

Put your used needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:

–

made of a heavy-duty plastic,

–

can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,

–

upright and stable during use,

–

leak-resistant, and

–

properly labeled to warn of hazardous waste inside the container.
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal
Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
The used Pen may be discarded in your household trash after you have removed the needle.

Storing your Pen

Unused Pens

Store unused Pens in the refrigerator at 36°F to 46°F (2°C to 8°C).
Do not freeze LYUMJEV. Do not use if it has been frozen.
Unused Pens may be used until the expiration date printed on the label if the Pen has been kept in the refrigerator.

In-use Pen

Store the Pen you are currently using at room temperature [up to 86°F (30°C)]. Keep away from heat and light.
Throw away the LYUMJEV KwikPen you are using after 28 days, even if it still has insulin left in it.

General information about the safe and effective use of your Pen

Keep your Pen and needles out of the sight and reach of children.
Do not use your Pen if any part looks broken or damaged.
Always carry an extra Pen in case yours is lost or damaged.

Troubleshooting

If you cannot remove the Pen cap, gently twist the cap back and forth, and then pull the cap straight off.
If the dose knob is hard to push:

–

pushing the dose knob more slowly will make it easier to inject.

–

your needle may be blocked. Put on a new needle and prime the Pen.

–

you may have dust, food, or liquid inside the Pen. Throw the Pen away and get a new Pen.

If you have any questions or problems with your LYUMJEV KwikPen, contact Lilly at 1-800-545-5979 or call your healthcare provider for help. For more information on LYUMJEV KwikPen and insulin, go to www.lyumjev.com.

Scan this code to launch

www.lyumjev.com

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Eli Lilly and Company
Indianapolis, IN 46285, USA
US License Number 1891

LYUMJEV™ and LYUMJEV™ KwikPen® are trademarks of Eli Lilly and Company.

LYUMJEV KwikPen meets the current dose accuracy and functional requirements of ISO 11608-1.

Issued: June 2020

LUMKP-0001-IFU-20200615

LYUMJEV JUNIOR KWIKPEN U-100 INSTRUCTIONS FOR USE

Instructions for Use

LYUMJEV™ Junior KwikPen®(LOOM-jehv)

(insulin lispro-aabc)

injection, for subcutaneous use

3 mL single-patient-use pen

100 units/mL

Read the Instructions for Use before you start taking LYUMJEV™ and each time you get another LYUMJEV Junior KwikPen. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

Do not share your LYUMJEV Junior KwikPen with other people, even if the needle has been changed. Do not reuse or share needles with other people. You may give other people a serious infection or get a serious infection from them.

LYUMJEV Junior KwikPen (“Pen”) is a disposable single-patient-use prefilled pen containing 300 units of LYUMJEV.

Your healthcare provider will tell you how many units to give as your dose and how to inject your prescribed dose of insulin.
You can give yourself more than 1 dose from the Pen.
Each turn of the dose knob dials 0.5 (½) unit of insulin. You can give from 0.5 (½) to 30 units in a single injection.
If your dose is more than 30 units, you will need to give yourself more than 1 injection. Always check the number in the dose window to make sure you dialed the correct dose.
The plunger only moves a little with each injection, and you may not notice that it moves. The plunger will only reach the end of the cartridge when you have used all 300 units in the Pen.

People who are blind or have vision problems should not use the Pen without help from a person trained to use the Pen.

How to recognize your LYUMJEV Junior KwikPen

Pen color:	Taupe
Dose knob:	Peach, with raised ridges on end and side
Label:	White with a peach color bar, and peach, light blue and dark blue color band

Supplies needed to give your injection

LYUMJEV Junior KwikPen, 100 units/mL
KwikPen compatible needle (Becton, Dickinson and Company Pen needles recommended)
Alcohol swab
Gauze (optional)

Preparing your Pen

Wash your hands with soap and water.
Check the Pen to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
Do not use your Pen past the expiration date printed on the label or for more than 28 days after you first start using the Pen.
Always use a new needle for each injection to help prevent infections and blocked needles.

Step 1: Pull the Pen cap straight off. – Do not remove the Pen label. Wipe the rubber seal with an alcohol swab.
Step 2: Check the liquid in the Pen. LYUMJEV should look clear and colorless. Do not use if it is cloudy, colored, or has particles or clumps in it.
Step 3: Select a new needle. Pull off the paper tab from the outer needle shield.
Step 4: Push the capped needle straight onto the Pen and twist the needle on until it is tight.
Step 5: Pull off the outer needle shield. Do not throw it away. Pull off the inner needle shield and throw it away.

Priming your Pen

Prime before each injection.

Priming your Pen means removing the air from the needle and cartridge that may collect during normal use and ensures that your Pen is working correctly.
If you do not prime before each injection, you may get too much or too little insulin.

Step 6:

To prime your Pen, turn the dose knob to select 2 units.

Step 7:

Hold your Pen with the needle pointing up. Tap the cartridge holder gently to collect air bubbles at the top.

Step 8:

Continue holding your Pen with the needle pointing up. Push the dose knob in until it stops and “0” is seen in the dose window. Hold the dose knob in and count to 5 slowly.

You should see insulin at the tip of the needle.

–: If you do not see insulin, repeat priming steps 6 to 8, but not more than 4 times.
–: If you still do not see insulin, change the needle and repeat priming steps 6 to 8.

Small air bubbles are normal and will not affect your dose.

Selecting your dose

You can give from 0.5 (½) to 30 units in a single injection.
If your dose is more than 30 units, you will need to give more than 1 injection.

–

If you need help with dividing up your dose the right way, ask your healthcare provider.

–

Use a new needle for each injection and repeat the priming steps.

–

If you usually need more than 30 units, ask your healthcare provider if a different LYUMJEV Pen would be better for you.

Step 9:

Turn the dose knob to select the number of units you need to inject. The dose indicator should line up with your dose.

–

The Pen dials 0.5 (½) unit at a time.

–

The dose knob clicks as you turn it.

–

Do not dial your dose by counting the clicks. You may dial the wrong dose. This may lead to you getting too much insulin or not enough insulin.

–

The dose can be corrected by turning the dose knob in either direction until the correct dose lines up with the dose indicator.

–

The whole unit numbers are printed on the dial. The example to the right shows 4 units in the dose window.

–

The half units are shown as lines between the whole unit numbers. The example to the right shows 10.5 units in the dose window.
Always check the number in the dose window to make sure you have dialed the correct dose.

Example: 4 units shown in the dose window

Example: 10.5 (10 ½) units shown in the dose window

The Pen will not let you dial more than the number of units left in the Pen.
If you need to inject more than the number of units left in the Pen, you may either:

–

inject the amount left in your Pen and then use a new Pen to give the rest of your dose,
or

–

get a new Pen and inject the full dose.
It is normal to see a small amount of insulin left in the Pen that you cannot inject.

Giving your injection

Inject your insulin as your healthcare provider has shown you.
Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
Do not use the exact same spot for each injection.
Do not inject where the skin has pits, is thickened, or has lumps.
Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
Do not try to change your dose while injecting.

Step 10: Choose your injection site. LYUMJEV is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms. Wipe your skin with an alcohol swab, and let your skin dry before you inject your dose.
Step 11: Insert the needle into your skin. Push the dose knob all the way in.
Continue to hold the dose knob in and slowly count to 5 before removing the needle. Do not try to inject your insulin by turning the dose knob. You will not receive your insulin by turning the dose knob.
Step 12: Pull the needle out of your skin. – A drop of insulin at the needle tip is normal. It will not affect your dose. Check the number in the dose window. – If you see “0” in the dose window, you have received the full amount you dialed. – If you do not see “0” in the dose window, you did not receive your full dose. Do not redial. Insert the needle into your skin and finish your injection. – If you still do not think you received the full amount you dialed for your injection, do not start over or repeat that injection. Monitor your blood glucose as instructed by your healthcare provider. – If you normally need to give 2 injections for your full dose, be sure to give your second injection. The plunger only moves a little with each injection, and you may not notice that it moves. If you see blood after you take the needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. Do not rub the area.

After your injection

Step 13: Carefully replace the outer needle shield.
Step 14: Unscrew the capped needle and throw it away (see Disposing of Pens and needles section). Do not store the Pen with the needle attached to prevent leaking, blocking the needle, and air from entering the Pen.
Step 15: Replace the Pen cap by lining up the cap clip with the dose indicator and pushing straight on.

Disposing of Pens and needles

Put your used needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:

–

made of a heavy-duty plastic,

–

can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,

–

upright and stable during use,

–

leak-resistant, and

–

properly labeled to warn of hazardous waste inside the container.
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal
Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
The used Pen may be discarded in your household trash after you have removed the needle.

Storing your Pen

Unused Pens

Store unused Pens in the refrigerator at 36°F to 46°F (2°C to 8°C).
Do not freeze LYUMJEV. Do not use if it has been frozen.
Unused Pens may be used until the expiration date printed on the label if the Pen has been kept in the refrigerator.

In-use Pen

Store the Pen you are currently using at room temperature [up to 86°F (30°C)]. Keep away from heat and light.
Throw away the LYUMJEV Junior KwikPen you are using after 28 days, even if it still has insulin left in it.

General information about the safe and effective use of your Pen

Keep your Pen and needles out of the sight and reach of children.
Do not use your Pen if any part looks broken or damaged.
Always carry an extra Pen in case yours is lost or damaged.

Troubleshooting

If you cannot remove the Pen cap, gently twist the cap back and forth, and then pull the cap straight off.
If the dose knob is hard to push:

–

pushing the dose knob more slowly will make it easier to inject.

–

your needle may be blocked. Put on a new needle and prime the Pen.

–

you may have dust, food, or liquid inside the Pen. Throw the Pen away and get a new Pen.

If you have any questions or problems with your LYUMJEV Junior KwikPen, contact Lilly at 1-800-545-5979 or call your healthcare provider for help. For more information on LYUMJEV Junior KwikPen and insulin, go to www.lyumjev.com.

Scan this code to launch

www.lyumjev.com

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Eli Lilly and Company
Indianapolis, IN 46285, USA
US License Number 1891

LYUMJEV™ and LYUMJEV™ Junior KwikPen® are trademarks of Eli Lilly and Company.

LYUMJEV Junior KwikPen meets the current dose accuracy and functional requirements of ISO 11608-1.

Issued: June 2020

LUMJRKP-0001-IFU-20200615

LYUMJEV TEMPO PEN U-100 INSTRUCTIONS FOR USE

Instructions for Use

LYUMJEV™ Tempo Pen™ (LOOM-jehv)

(insulin lispro-aabc)

injection, for subcutaneous use

3 mL single-patient-use pen

100 units/mL

Read the Instructions for Use before you start taking LYUMJEV™ and each time you get another LYUMJEV Tempo Pen. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

Do not share your LYUMJEV Tempo Pen with other people, even if the needle has been changed. Do not reuse or share needles with other people. You may give other people a serious infection or get a serious infection from them.

LYUMJEV Tempo Pen (“Pen”) is a disposable single-patient-use prefilled pen containing 300 units of LYUMJEV.

Your healthcare provider will tell you how many units to give as your dose and how to inject your prescribed dose of insulin.
You can give yourself more than 1 dose from the Pen.
Each turn of the dose knob dials 1 unit of insulin. You can give from 1 to 60 units in a single injection.
If your dose is more than 60 units, you will need to give yourself more than 1 injection. Always check the number in the dose window to make sure you dialed the correct dose.
The plunger only moves a little with each injection, and you may not notice that it moves. The plunger will only reach the end of the cartridge when you have used all 300 units in the Pen.
This LYUMJEV Tempo Pen contains a component that allows for data connectivity when used with a compatible transmitter.

People who are blind or have vision problems should not use the Pen without help from a person trained to use the Pen.

How to recognize your LYUMJEV Tempo Pen

Pen color:	Taupe
Dose Knob:	Blue, with raised ridges around the entire side
Label:	Blue and white

Supplies needed to give your injection

LYUMJEV Tempo Pen, 100 units/mL
Tempo Pen compatible needle (Becton, Dickinson and Company Pen needles recommended)
Alcohol swab
Gauze (optional)

Preparing your Pen

Wash your hands with soap and water.
Check the Pen to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
Do not use your Pen past the expiration date printed on the label or for more than 28 days after you first start using the Pen.
Always use a new needle for each injection to help prevent infections and blocked needles.

Step 1: Pull the Pen cap straight off. – Do not remove the Pen label. Wipe the rubber seal with an alcohol swab.
Step 2: Check the liquid in the Pen. LYUMJEV should look clear and colorless. Do not use if it is cloudy, colored, or has particles or clumps in it.
Step 3: Select a new needle. Pull off the paper tab from the outer needle shield.
Step 4: Push the capped needle straight onto the Pen and twist the needle on until it is tight.
Step 5: Pull off the outer needle shield. Do not throw it away. Pull off the inner needle shield and throw it away.

Priming your Pen

Prime before each injection.

Priming your Pen means removing the air from the needle and cartridge that may collect during normal use and ensures that your Pen is working correctly.
If you do not prime before each injection, you may get too much or too little insulin.

Step 6:

To prime your Pen, turn the dose knob to select 2 units.

Step 7:

Hold your Pen with the needle pointing up. Tap the cartridge holder gently to collect air bubbles at the top.

Step 8:

Continue holding your Pen with the needle pointing up. Push the dose knob in until it stops and “0” is seen in the dose window. Hold the dose knob in and count to 5 slowly.

You should see insulin at the tip of the needle.

–: If you do not see insulin, repeat priming steps 6 to 8, but not more than 4 times.
–: If you still do not see insulin, change the needle and repeat priming steps 6 to 8.

Small air bubbles are normal and will not affect your dose.

Selecting your dose

You can give from 1 to 60 units in a single injection.
If your dose is more than 60 units, you will need to give more than 1 injection.

–

If you need help with dividing up your dose the right way, ask your healthcare provider.

–

Use a new needle for each injection and repeat the priming steps.

Step 9:

Turn the dose knob to select the number of units you need to inject. The dose indicator should line up with your dose.

–

The Pen dials 1 unit at a time.

–

The dose knob clicks as you turn it.

–

Do not dial your dose by counting the clicks. You may dial the wrong dose. This may lead to you getting too much insulin or not enough insulin.

–

The dose can be corrected by turning the dose knob in either direction until the correct dose lines up with the dose indicator.

–

The even numbers are printed on the dial. The example to the right shows 12 units in the dose window.

–

The odd numbers, after the number 1, are shown as full lines between the numbers. The example to the right shows 25 units in the dose window.
Always check the number in the dose window to make sure you have dialed the correct dose.

Example: 12 units shown in the dose window

Example: 25 units shown in the dose window

The Pen will not let you dial more than the number of units left in the Pen.
If you need to inject more than the number of units left in the Pen, you may either:

–

inject the amount left in your Pen and then use a new Pen to give the rest of your dose,
or

–

get a new Pen and inject the full dose.
It is normal to see a small amount of insulin left in the Pen that you cannot inject.

Giving your injection

Inject your insulin as your healthcare provider has shown you.
Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
Do not use the exact same spot for each injection.
Do not inject where the skin has pits, is thickened, or has lumps.
Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
Do not try to change your dose while injecting.

Step 10: Choose your injection site. LYUMJEV is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms. Wipe your skin with an alcohol swab, and let your skin dry before you inject your dose.
Step 11: Insert the needle into your skin. Push the dose knob all the way in.
Continue to hold the dose knob in and slowly count to 5 before removing the needle. Do not try to inject your insulin by turning the dose knob. You will not receive your insulin by turning the dose knob.
Step 12: Pull the needle out of your skin. – A drop of insulin at the needle tip is normal. It will not affect your dose. Check the number in the dose window. – If you see “0” in the dose window, you have received the full amount you dialed. – If you do not see “0” in the dose window, you did not receive your full dose. Do not redial. Insert the needle into your skin and finish your injection. – If you still do not think you received the full amount you dialed for your injection, do not start over or repeat that injection. Monitor your blood glucose as instructed by your healthcare provider. – If you normally need to give 2 injections for your full dose, be sure to give your second injection. The plunger only moves a little with each injection, and you may not notice that it moves. If you see blood after you take the needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. Do not rub the area.

After your injection

Step 13: Carefully replace the outer needle shield.
Step 14: Unscrew the capped needle and throw it away (see Disposing of Pens and needles section). Do not store the Pen with the needle attached to prevent leaking, blocking the needle, and air from entering the Pen.
Step 15: Replace the Pen cap by lining up the cap clip with the dose indicator and pushing straight on.

Disposing of Pens and needles

Put your used needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:

–

made of a heavy-duty plastic,

–

can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,

–

upright and stable during use,

–

leak-resistant, and

–

properly labeled to warn of hazardous waste inside the container.
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal
Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
The used Pen may be discarded in your household trash after you have removed the needle.

Storing your Pen

Unused Pens

Store unused Pens in the refrigerator at 36°F to 46°F (2°C to 8°C).
Do not freeze LYUMJEV. Do not use if it has been frozen.
Unused Pens may be used until the expiration date printed on the label if the Pen has been kept in the refrigerator.

In-use Pen

Store the Pen you are currently using at room temperature [up to 86°F (30°C)]. Keep away from heat and light.
Throw away the LYUMJEV Tempo Pen you are using after 28 days, even if it still has insulin left in it.

General information about the safe and effective use of your Pen

Keep your Pen and needles out of the sight and reach of children.
Do not use your Pen if any part looks broken or damaged.
Always carry an extra Pen in case yours is lost or damaged.

Troubleshooting

If you cannot remove the Pen cap, gently twist the cap back and forth, and then pull the cap straight off.
If the dose knob is hard to push:

–

pushing the dose knob more slowly will make it easier to inject.

–

your needle may be blocked. Put on a new needle and prime the Pen.

–

you may have dust, food, or liquid inside the Pen. Throw the Pen away and get a new Pen.

If you have any questions or problems with your LYUMJEV Tempo Pen, contact Lilly at 1-800-545-5979 or call your healthcare provider for help. For more information on LYUMJEV Tempo Pen and insulin, go to www.lyumjev.com.

Scan this code to launch

www.lyumjev.com

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Eli Lilly and Company
Indianapolis, IN 46285, USA
US License Number 1891

LYUMJEV™ and LYUMJEV™ Tempo Pen™ are trademarks of Eli Lilly and Company.

LYUMJEV Tempo Pen meets the current dose accuracy and functional requirements of ISO 11608-1.

Issued: June 2020

LUMTP-0001-IFU-20200615

LYUMJEV KWIKPEN U-200 INSTRUCTIONS FOR USE

Instructions for Use

LYUMJEV™ KwikPen®(LOOM-jehv)

(insulin lispro-aabc)

injection, for subcutaneous use

3 mL single-patient-use pen

200 units/mL

LYUMJEV KwikPen (“Pen”) is a disposable single-patient-use prefilled pen containing 600 units of LYUMJEV.

Your healthcare provider will tell you how many units to give as your dose and how to inject your prescribed dose of insulin.
You can give yourself more than 1 dose from the Pen.
Each turn of the dose knob dials 1 unit of insulin. You can give from 1 to 60 units in a single injection.
If your dose is more than 60 units, you will need to give yourself more than 1 injection. Always check the number in the dose window to make sure you dialed the correct dose.
The plunger only moves a little with each injection, and you may not notice that it moves. The plunger will only reach the end of the cartridge when you have used all 600 units in the Pen.

LYUMJEV KwikPen is available in two strengths, 100 units/mL and 200 units/mL. Inject LYUMJEV 200 units/mL only with your Pen. Do not transfer insulin from your Pen to a syringe. Syringes will not measure 200 units/mL of insulin correctly. A severe overdose can result, causing very low blood sugar which may put your life in danger.

People who are blind or have vision problems should not use the Pen without help from a person trained to use the Pen.

How to recognize your LYUMJEV KwikPen

Pen color:	Taupe
Dose Knob:	Taupe, with raised ridges on side
Label:	White with a blue color bar and checkerboard design with “200 units per mL (U-200)” in a yellow stripe. Yellow warning on cartridge holder.

Supplies needed to give your injection

LYUMJEV KwikPen, 200 units/mL
KwikPen compatible needle (Becton, Dickinson and Company Pen needles recommended)
Alcohol swab
Gauze (optional)

Preparing your Pen

Wash your hands with soap and water.
Check the Pen to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
Do not use your Pen past the expiration date printed on the label or for more than 28 days after you first start using the Pen.
Always use a new needle for each injection to help prevent infections and blocked needles.

Step 1: Pull the Pen cap straight off. – Do not remove the Pen label. Wipe the rubber seal with an alcohol swab.
Step 2: Check the liquid in the Pen. LYUMJEV should look clear and colorless. Do not use if it is cloudy, colored, or has particles or clumps in it.
Step 3: Select a new needle. Pull off the paper tab from the outer needle shield.
Step 4: Push the capped needle straight onto the Pen and twist the needle on until it is tight.
Step 5: Pull off the outer needle shield. Do not throw it away. Pull off the inner needle shield and throw it away.

Priming your Pen

Prime before each injection.

Priming your Pen means removing the air from the needle and cartridge that may collect during normal use and ensures that your Pen is working correctly.
If you do not prime before each injection, you may get too much or too little insulin.

Step 6:

To prime your Pen, turn the dose knob to select 2 units.

Step 7:

Hold your Pen with the needle pointing up. Tap the cartridge holder gently to collect air bubbles at the top.

Step 8:

Continue holding your Pen with the needle pointing up. Push the dose knob in until it stops and “0” is seen in the dose window. Hold the dose knob in and count to 5 slowly.

You should see insulin at the tip of the needle.

–: If you do not see insulin, repeat priming steps 6 to 8, but not more than 8 times.
–: If you still do not see insulin, change the needle and repeat priming steps 6 to 8.

Small air bubbles are normal and will not affect your dose.

Selecting your dose

This Pen has been designed to deliver the dose that is shown in the dose window. Dial your usual dose as instructed by your healthcare provider.

You can give from 1 to 60 units in a single injection.
If your dose is more than 60 units, you will need to give more than 1 injection.

–

If you need help dividing up your dose the right way, ask your healthcare provider.

–

Use a new needle for each injection and repeat the priming steps.

Step 9:

Turn the dose knob to select the number of units you need to inject. The dose indicator should line up with your dose.

–

The Pen dials 1 unit at a time.

–

The dose knob clicks as you turn it.

–

Do not dial your dose by counting the clicks. You may dial the wrong dose. This may lead to you getting too much insulin or not enough insulin.

–

The dose can be corrected by turning the dose knob in either direction until the correct dose lines up with the dose indicator.

–

The even numbers are printed on the dial. The example to the right shows 12 units in the dose window.

–

The odd numbers, after the number 1, are shown as full lines between the numbers. The example to the right shows 25 units in the dose window.
Always check the number in the dose window to make sure you have dialed the correct dose.

Example: 12 units shown in the dose window

Example: 25 units shown in the dose window

The Pen will not let you dial more than the number of units left in the Pen.
If you need to inject more than the number of units left in the Pen, you may either:

–

inject the amount left in your Pen and then use a new Pen to give the rest of your dose,
or

–

get a new Pen and inject the full dose.
It is normal to see a small amount of insulin left in the Pen that you cannot inject. Do not transfer this to a syringe. Severe overdose can result.

Giving your injection

Inject your insulin as your healthcare provider has shown you.
Change (rotate) your injection sites within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
Do not use the exact same spot for each injection.
Do not inject where the skin has pits, is thickened, or has lumps.
Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
Do not try to change your dose while injecting.

Step 10: Choose your injection site. LYUMJEV is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms. Wipe your skin with an alcohol swab, and let your skin dry before you inject your dose.
Step 11: Insert the needle into your skin. Push the dose knob all the way in.
Continue to hold the dose knob in and slowly count to 5 before removing the needle. Do not try to inject your insulin by turning the dose knob. You will not receive your insulin by turning the dose knob.
Step 12: Pull the needle out of your skin. – A drop of insulin at the needle tip is normal. It will not affect your dose. Check the number in the dose window. – If you see “0” in the dose window, you have received the full amount you dialed. – If you do not see “0” in the dose window, you did not receive your full dose. Do not redial. Insert the needle into your skin and finish your injection. – If you still do not think you received the full amount you dialed for your injection, do not start over or repeat that injection. Monitor your blood glucose as instructed by your healthcare provider. – If you normally need to give 2 injections for your full dose, be sure to give your second injection. The plunger only moves a little with each injection, and you may not notice that it moves. If you see blood after you take the needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. Do not rub the area.

After your injection

Step 13: Carefully replace the outer needle shield
Step 14: Unscrew the capped needle and throw it away (see Disposing of Pens and needles section). Do not store the Pen with the needle attached to prevent leaking, blocking the needle, and air from entering the Pen.
Step 15: Replace the Pen cap by lining up the cap clip with the dose indicator and pushing straight on.

Disposing of Pens and needles

Put your used needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:

–

made of a heavy-duty plastic,

–

can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,

–

upright and stable during use,

–

leak-resistant, and

–

properly labeled to warn of hazardous waste inside the container.
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal
Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
The used Pen may be discarded in your household trash after you have removed the needle.

Storing your Pen

Unused Pens

Store unused Pens in the refrigerator at 36°F to 46°F (2°C to 8°C).
Do not freeze LYUMJEV. Do not use if it has been frozen.
Unused Pens may be used until the expiration date printed on the label if the Pen has been kept in the refrigerator.

In-use Pen

Store the Pen you are currently using at room temperature [up to 86°F (30°C)]. Keep away from heat and light.
Throw away the LYUMJEV KwikPen you are using after 28 days, even if it still has insulin left in it.

General information about the safe and effective use of your Pen

Keep your Pen and needles out of the sight and reach of children.
Do not use your Pen if any part looks broken or damaged.
Always carry an extra Pen in case yours is lost or damaged.

Troubleshooting

If you cannot remove the Pen cap, gently twist the cap back and forth, and then pull the cap straight off.
If the dose knob is hard to push:

–

pushing the dose knob more slowly will make it easier to inject.

–

your needle may be blocked. Put on a new needle and prime the Pen.

–

you may have dust, food, or liquid inside the Pen. Throw the Pen away and get a new Pen.

Scan this code to launch

www.lyumjev.com

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Eli Lilly and Company
Indianapolis, IN 46285, USA
US License Number 1891

LYUMJEV™ and LYUMJEV™ KwikPen® are trademarks of Eli Lilly and Company.

LYUMJEV KwikPen meets the current dose accuracy and functional requirements of ISO 11608-1.

Issued: June 2020

LUMKP200-0001-IFU-20200615

PACKAGE LABEL – LYUMJEV U100 Vial Carton

NDC 0002-7728-01

LYUMJEVTM

(insulin lispro-aabc)

injection

100 units per mL (U-100)

for subcutaneous or intravenous use

10 mL multiple-dose vial

Rx only

www.lyumjev.com

Lilly

PACKAGE LABEL – LYUMJEV U100 Vial Carton

PACKAGE LABEL – LYUMJEV U100 Cartridges 5 Count Carton

NDC 0002-7726-05

5 x 3 mL Cartridges

LYUMJEVTM

(insulin lispro-aabc)

injection

For Single Patient Use Only

100 units per mL (U-100)

For subcutaneous use

Rx only

For use in Eli Lilly and Company's HumaPen® LUXURA®HD and other compatible insulin delivery devices.

www.lyumjev.com

Lilly

PACKAGE LABEL – LYUMJEV U100 Cartridges 5 Count Carton

PACKAGE LABEL – LYUMJEV U100 KwikPen 5 Count Carton

Dispense in this sealed carton.

NDC 0002-8207-05

LYUMJEVTM KwikPen®

(insulin lispro-aabc)

injection

For Single Patient Use Only

100 units per mL (U-100)

For subcutaneous use

5 x 3 mL prefilled pens

Rx only

Needles not included

This device is recommended for use with Becton, Dickinson and Company's insulin pen needles.

Lilly

PACKAGE LABEL – LYUMJEV U100 KwikPen 5 Count Carton

PACKAGE LABEL – LYUMJEV U100 Junior KwikPen 5 Count Carton

Dispense in this sealed carton.

NDC 0002-8351-05

LYUMJEVTM

Junior KwikPen®

(insulin lispro-aabc)

injection

For Single Patient Use Only

100 units per mL (U-100)

This pen can deliver 0.5 (1/2) to 30 units in one injection.

5 x 3 mL prefilled pens

For subcutaneous use

Rx only

Needles not included

This device is recommended for use with Becton, Dickinson and Company's insulin pen needles.

Lilly

PACKAGE LABEL – LYUMJEV U100 Junior KwikPen 5 Count Carton

PACKAGE LABEL – LYUMJEV U100 Tempo Pen 5 Count Carton

Dispense in this sealed carton.

NDC 0002-8235-05

LYUMJEVTM Tempo PenTM

(insulin lispro-aabc)

injection

For Single Patient Use Only

100 units per mL (U-100)

For subcutaneous use

5 x 3 mL prefilled pens

Rx only

Needles not included

This device is recommended for use with Becton, Dickinson and Company's insulin pen needles.

Lilly

PACKAGE LABEL – LYUMJEV U100 Tempo Pen 5 Count Carton

PACKAGE LABEL – LYUMJEV U200 KwikPen 5 Count Carton

Dispense in this sealed carton.

NDC 0002-8228-27

LYUMJEVTM KwikPen®

(insulin lispro-aabc)

injection

For Single Patient Use Only

200 units per mL (U-200)

For subcutaneous use

2 x 3 mL prefilled pens

Rx only

Needles not included

This device is recommended for use with Becton, Dickinson and Company's insulin pen needles.

Lilly

DO NOT TRANSFER TO A SYRINGE SEVERE OVERDOSE CAN RESULT

PACKAGE LABEL – LYUMJEV U200 KwikPen 5 Count Carton

LYUMJEV
insulin lispro-aabc injection, solution

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0002-7728
Route of Administration	INTRAVENOUS, SUBCUTANEOUS

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
Insulin lispro (UNII: GFX7QIS1II) (Insulin lispro - UNII:GFX7QIS1II)	Insulin lispro	100 [iU] in 1 mL

Ingredient Name	Strength
Inactive Ingredients
Treprostinil sodium (UNII: 7JZ75N2NT6)	1.06 ug in 1 mL
Trisodium citrate dihydrate (UNII: B22547B95K)	4.41 mg in 1 mL
Zinc oxide (UNII: SOI2LOH54Z)
Magnesium chloride (UNII: 02F3473H9O)	1.02 mg in 1 mL
Metacresol (UNII: GGO4Y809LO)	3.15 mg in 1 mL
Glycerin (UNII: PDC6A3C0OX)	12.1 mg in 1 mL
Hydrochloric acid (UNII: QTT17582CB)
Sodium hydroxide (UNII: 55X04QC32I)
Water (UNII: 059QF0KO0R)

#	Item Code	Package Description	Marketing Start Date
Packaging
1	NDC:0002-7728-01	1 in 1 CARTON	06/15/2020
1		10 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product
2	NDC:0002-7728-99	1 in 1 CARTON	06/15/2020
2		10 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Marketing Information
BLA	BLA761109	06/15/2020

LYUMJEV
insulin lispro-aabc injection, solution

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0002-7726
Route of Administration	SUBCUTANEOUS

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
Insulin lispro (UNII: GFX7QIS1II) (Insulin lispro - UNII:GFX7QIS1II)	Insulin lispro	100 [iU] in 1 mL

Ingredient Name	Strength
Inactive Ingredients
Treprostinil sodium (UNII: 7JZ75N2NT6)	1.06 ug in 1 mL
Trisodium citrate dihydrate (UNII: B22547B95K)	4.41 mg in 1 mL
Zinc oxide (UNII: SOI2LOH54Z)
Magnesium chloride (UNII: 02F3473H9O)	1.02 mg in 1 mL
Metacresol (UNII: GGO4Y809LO)	3.15 mg in 1 mL
Glycerin (UNII: PDC6A3C0OX)	12.1 mg in 1 mL
Hydrochloric acid (UNII: QTT17582CB)
Sodium hydroxide (UNII: 55X04QC32I)
Water (UNII: 059QF0KO0R)

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
Packaging
1	NDC:0002-7726-05	5 in 1 CARTON	06/15/2020	06/15/2020
1	NDC:0002-7726-01	3 mL in 1 CARTRIDGE; Type 0: Not a Combination Product

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Marketing Information
BLA	BLA761109	06/15/2020	06/15/2020

LYUMJEV KWIKPEN
insulin lispro-aabc injection, solution

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0002-8207
Route of Administration	SUBCUTANEOUS

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
Insulin lispro (UNII: GFX7QIS1II) (Insulin lispro - UNII:GFX7QIS1II)	Insulin lispro	100 [iU] in 1 mL

Ingredient Name	Strength
Inactive Ingredients
Treprostinil sodium (UNII: 7JZ75N2NT6)	1.06 ug in 1 mL
Trisodium citrate dihydrate (UNII: B22547B95K)	4.41 mg in 1 mL
Zinc oxide (UNII: SOI2LOH54Z)
Magnesium chloride (UNII: 02F3473H9O)	1.02 mg in 1 mL
Metacresol (UNII: GGO4Y809LO)	3.15 mg in 1 mL
Glycerin (UNII: PDC6A3C0OX)	12.1 mg in 1 mL
Hydrochloric acid (UNII: QTT17582CB)
Sodium hydroxide (UNII: 55X04QC32I)
Water (UNII: 059QF0KO0R)

#	Item Code	Package Description	Marketing Start Date
Packaging
1	NDC:0002-8207-05	5 in 1 CARTON	06/15/2020
1	NDC:0002-8207-01	3 mL in 1 SYRINGE; Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)
2	NDC:0002-8207-61	1 in 1 CARTON	06/15/2020
2		3 mL in 1 SYRINGE; Type 1: Convenience Kit of Co-Package

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Marketing Information
BLA	BLA761109	06/15/2020

LYUMJEV JUNIOR KWIKPEN
insulin lispro-aabc injection, solution

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0002-8351
Route of Administration	SUBCUTANEOUS

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
Insulin lispro (UNII: GFX7QIS1II) (Insulin lispro - UNII:GFX7QIS1II)	Insulin lispro	100 [iU] in 1 mL

Ingredient Name	Strength
Inactive Ingredients
Treprostinil sodium (UNII: 7JZ75N2NT6)	1.06 ug in 1 mL
Trisodium citrate dihydrate (UNII: B22547B95K)	4.41 mg in 1 mL
Zinc oxide (UNII: SOI2LOH54Z)
Magnesium chloride (UNII: 02F3473H9O)	1.02 mg in 1 mL
Metacresol (UNII: GGO4Y809LO)	3.15 mg in 1 mL
Glycerin (UNII: PDC6A3C0OX)	12.1 mg in 1 mL
Hydrochloric acid (UNII: QTT17582CB)
Sodium hydroxide (UNII: 55X04QC32I)
Water (UNII: 059QF0KO0R)

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
Packaging
1	NDC:0002-8351-05	5 in 1 CARTON	06/15/2020	06/15/2020
1	NDC:0002-8351-01	3 mL in 1 SYRINGE; Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Marketing Information
BLA	BLA761109	06/15/2020	06/15/2020

LYUMJEV TEMPO PEN
insulin lispro-aabc injection, solution

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0002-8235
Route of Administration	SUBCUTANEOUS

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
Insulin lispro (UNII: GFX7QIS1II) (Insulin lispro - UNII:GFX7QIS1II)	Insulin lispro	100 [iU] in 1 mL

Ingredient Name	Strength
Inactive Ingredients
Treprostinil sodium (UNII: 7JZ75N2NT6)	1.06 ug in 1 mL
Trisodium citrate dihydrate (UNII: B22547B95K)	4.41 mg in 1 mL
Zinc oxide (UNII: SOI2LOH54Z)
Magnesium chloride (UNII: 02F3473H9O)	1.02 mg in 1 mL
Metacresol (UNII: GGO4Y809LO)	3.15 mg in 1 mL
Glycerin (UNII: PDC6A3C0OX)	12.1 mg in 1 mL
Hydrochloric acid (UNII: QTT17582CB)
Sodium hydroxide (UNII: 55X04QC32I)
Water (UNII: 059QF0KO0R)

#	Item Code	Package Description	Marketing Start Date
Packaging
1	NDC:0002-8235-05	5 in 1 CARTON	09/29/2022
1	NDC:0002-8235-01	3 mL in 1 SYRINGE; Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Marketing Information
BLA	BLA761109	06/15/2020

LYUMJEV KWIKPEN
insulin lispro-aabc injection, solution

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0002-8228
Route of Administration	SUBCUTANEOUS

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
Insulin lispro (UNII: GFX7QIS1II) (Insulin lispro - UNII:GFX7QIS1II)	Insulin lispro	200 [iU] in 1 mL

Ingredient Name	Strength
Inactive Ingredients
Treprostinil sodium (UNII: 7JZ75N2NT6)	1.06 ug in 1 mL
Trisodium citrate dihydrate (UNII: B22547B95K)	4.41 mg in 1 mL
Zinc oxide (UNII: SOI2LOH54Z)
Magnesium chloride (UNII: 02F3473H9O)	1.02 mg in 1 mL
Metacresol (UNII: GGO4Y809LO)	3.15 mg in 1 mL
Glycerin (UNII: PDC6A3C0OX)	12.1 mg in 1 mL
Hydrochloric acid (UNII: QTT17582CB)
Sodium hydroxide (UNII: 55X04QC32I)
Water (UNII: 059QF0KO0R)

#	Item Code	Package Description	Marketing Start Date
Packaging
1	NDC:0002-8228-27	2 in 1 CARTON	06/15/2020
1	NDC:0002-8228-01	3 mL in 1 SYRINGE; Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Marketing Information
BLA	BLA761109	06/15/2020

Labeler - Eli Lilly and Company (006421325)

Name	Drug Class	Updated
Fidanacogene Elaparvovec	Drugs	03-Oct-2024
Cerave Anti-Itch	Drugs	02-Oct-2024
Centrum Adult	Drugs	02-Oct-2024
Crovalimab	Drugs	02-Oct-2024
Cyltezo Prefilled Syringe	Drugs	01-Oct-2024
Zepbound Pen	Drugs	30-Sep-2024
Mylanta One	Drugs	27-Sep-2024
Uretron Ds	Drugs	27-Sep-2024
Medihoney Wound And Burn Dressing	Drugs	26-Sep-2024
Lidotrode	Drugs	26-Sep-2024
Libervant	Drugs	26-Sep-2024
Moderna Covid-19	Drugs	25-Sep-2024
Beqvez	Drugs	24-Sep-2024
Beqvez	Drugs	24-Sep-2024
Beqvez	Drugs	24-Sep-2024

Highlights of Prescribing Information

Recent Major Changes

Indications and Usage for Lyumjev

Lyumjev Dosage and Administration

Dosage Forms and Strengths

Contraindications

Warnings and Precautions

Adverse Reactions/Side Effects

Drug Interactions

Related/similar drugs

Full Prescribing Information

1. Indications and Usage for Lyumjev

2. Lyumjev Dosage and Administration

2.1 Important Administration Instructions

2.2 Route of Administration Instructions

2.3 General Dosage Instructions

3. Dosage Forms and Strengths

4. Contraindications

5. Warnings and Precautions

5.1 Never Share a LYUMJEV Prefilled Pen, Cartridge, or Syringe Between Patients

5.2 Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen

5.3 Hypoglycemia

5.4 Hypoglycemia Due to Medication Errors

5.5 Hypokalemia

5.6 Hypersensitivity Reactions

5.7 Fluid Retention and Heart Failure with Concomitant Use of PPAR-Gamma Agonists

5.8 Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction

6. Adverse Reactions/Side Effects

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

7. Drug Interactions

8. Use In Specific Populations

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairment

8.7 Hepatic Impairment

10. Overdosage

11. Lyumjev Description

12. Lyumjev - Clinical Pharmacology

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

12.6 Immunogenicity

13. Nonclinical Toxicology

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14. Clinical Studies

14.1 Overview of Clinical Studies

14.2 Adults with Type 1 Diabetes

14.3 Adults with Type 2 Diabetes

14.4 Adults with Type 1 Diabetes – Continuous Subcutaneous Insulin Infusion (CSII)

14.5 Pediatric Patients with Type 1 Diabetes

16. How is Lyumjev supplied

16.1 How Supplied

16.2 Storage and Handling

17. Patient Counseling Information

LYUMJEV PATIENT PACKAGE INSERT

LYUMJEV VIAL U-100 INSTRUCTIONS FOR USE

LYUMJEV KWIKPEN U-100 INSTRUCTIONS FOR USE

LYUMJEV JUNIOR KWIKPEN U-100 INSTRUCTIONS FOR USE

LYUMJEV TEMPO PEN U-100 INSTRUCTIONS FOR USE

LYUMJEV KWIKPEN U-200 INSTRUCTIONS FOR USE

Latest News

Cholesterol and dementia: What is the link?

Related Drugs

Categories

About US

Quick Link

Drugs

News

Find US